{"meta":{"query_hash":"f371b832babb","filters":{"venue":"European Heart Journal - Cardiovascular Pharmacotherapy"},"cohort_total":76,"direct_labels_cover":0,"predictions_cover":76,"exported":76,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f371b832babb","api":"https://metacan.xera.ac/api/v1/cohort?venue=European+Heart+Journal+-+Cardiovascular+Pharmacotherapy"},"results":[{"id":"W2171346361","doi":"10.1093/ehjcvp/pvu024","title":"Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial","year":2015,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; University of Alberta","funders":"","keywords":"Apixaban; Atrial fibrillation; Medicine; Diabetes mellitus; Internal medicine; Clinical trial; Cardiology; Randomized controlled trial; Intensive care medicine; Warfarin; Rivaroxaban; Endocrinology","score_opus":0.09513317404827838,"score_gpt":0.3497032654222461,"score_spread":0.25457009137396774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171346361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469155,0.0025214916,0.00011526955,0.0008908798,0.00043863757,0.0009588126,0.00002946591,0.000039407816,0.00031448455],"genre_scores_gemma":[0.9919895,0.00059119763,0.000819149,0.0002649665,0.0060849586,4.133326e-7,0.000060179955,0.000065130735,0.00012453544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966049,0.0012898515,0.0007448738,0.00029266754,0.000866471,0.00020121381],"domain_scores_gemma":[0.9982619,0.00048236336,0.00033348863,0.0003899335,0.00029266917,0.00023959899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027909384,0.00022887775,0.00080341205,0.00007998802,0.00012994472,0.00007159454,0.00009515237,0.00004155323,0.000023090206],"category_scores_gemma":[0.00026242796,0.00011746558,0.0009415338,0.0001894165,0.00013369657,0.00016470042,0.000031851567,0.00025664188,0.000011830534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044761248,0.000013073782,0.9291802,0.0000038772623,0.0053008785,0.000017103834,0.00018036901,0.00046497502,0.000014876678,9.189163e-7,0.0009076265,0.019154828],"study_design_scores_gemma":[0.14826906,0.0013090996,0.70027405,0.00003909791,0.0013230859,0.000006194959,0.0000373134,0.00004821809,0.00004372938,0.000004994267,0.14850017,0.00014500499],"about_ca_topic_score_codex":0.00001942748,"about_ca_topic_score_gemma":6.65396e-7,"teacher_disagreement_score":0.2289062,"about_ca_system_score_codex":0.000030653846,"about_ca_system_score_gemma":0.00006582864,"threshold_uncertainty_score":0.47901073},"labels":[],"label_agreement":null},{"id":"W2172979411","doi":"10.1093/ehjcvp/pvu010","title":"ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry","year":2015,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Norwegian; Medicine; Heart failure; Intensive care medicine; Internal medicine","score_opus":0.06523569821650542,"score_gpt":0.31271925804411677,"score_spread":0.24748355982761133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172979411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705726,0.004261307,0.00034863706,0.02130908,0.0008680231,0.0014641879,0.000041129693,0.00013761001,0.0009974088],"genre_scores_gemma":[0.97931,0.0006834575,0.005171211,0.011611006,0.0017780884,0.00002317319,0.00008547376,0.00020710919,0.0011304752],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957818,0.0013250074,0.0006421449,0.0004890213,0.0012142399,0.0005478091],"domain_scores_gemma":[0.9978444,0.00007623692,0.00016369476,0.00076715293,0.0006628294,0.00048570245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002843522,0.00041418002,0.00078810315,0.00011041074,0.00018950125,0.00016657509,0.00028930712,0.00006702046,0.0001737704],"category_scores_gemma":[0.00018397853,0.00025883474,0.0007712101,0.0004086078,0.00009017188,0.00022710288,0.000064407606,0.0007345184,0.00014741559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011907021,0.0006762987,0.43146116,0.000015723228,0.0075769434,0.00079905236,0.0013698341,0.00020952614,0.001299386,0.0000013266148,0.543408,0.0119920485],"study_design_scores_gemma":[0.02039893,0.0007889766,0.18896545,0.00032823856,0.000590865,0.00011622729,0.00031822076,0.00008552689,0.0004240881,0.0000064843357,0.7876066,0.0003703726],"about_ca_topic_score_codex":0.0002168617,"about_ca_topic_score_gemma":0.00002407747,"teacher_disagreement_score":0.24419862,"about_ca_system_score_codex":0.00023029745,"about_ca_system_score_gemma":0.00021371497,"threshold_uncertainty_score":0.9999864},"labels":[],"label_agreement":null},{"id":"W2180207772","doi":"10.1093/ehjcvp/pvv023","title":"Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality?","year":2015,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Myocardial infarction; Cardiology; Angioplasty; Revascularization; Relative risk; Coronary artery disease; Primary angioplasty; Creatine kinase; Confidence interval; Percutaneous coronary intervention","score_opus":0.14458606555825107,"score_gpt":0.3832812801725029,"score_spread":0.23869521461425183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180207772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03363122,0.9636678,0.000038551363,0.000018943634,0.0001982267,0.001473447,0.00032051877,0.00002886897,0.00062241266],"genre_scores_gemma":[0.0045195865,0.993935,0.0002254121,0.00023858283,0.00023225487,0.000047765996,0.00036284735,0.00018078102,0.0002578032],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9924541,0.0025407854,0.002057651,0.0006552505,0.0017950766,0.00049712544],"domain_scores_gemma":[0.99677074,0.00015065495,0.0006994657,0.0008697231,0.00090984604,0.0005995932],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0022207575,0.00079478795,0.0091759255,0.0013574082,0.00007033444,0.00003627886,0.000263732,0.00023420116,0.00036908966],"category_scores_gemma":[0.00006336732,0.00046476803,0.01176507,0.0018408711,0.000139017,0.00018819416,0.00006579001,0.00095166574,0.000008871778],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038053757,0.00074885477,0.009267849,0.0018280288,0.8913586,0.0013976713,0.00017055619,0.00007518001,0.00003449227,3.0043057e-7,0.00052973186,0.09078333],"study_design_scores_gemma":[0.0064562717,0.00094652676,0.0031679142,0.0008986944,0.5602065,0.0005541021,0.0000065550157,0.000009237157,0.0000046960195,2.7980477e-7,0.42740858,0.00034066994],"about_ca_topic_score_codex":0.000047979982,"about_ca_topic_score_gemma":0.0000017209917,"teacher_disagreement_score":0.42687884,"about_ca_system_score_codex":0.00026765853,"about_ca_system_score_gemma":0.0006866967,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2606920147","doi":"10.1093/ehjcvp/pvx007","title":"Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review","year":2017,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Merck Sharp and Dohme; Servier; Amarin Corporation; Sanofi; GlaxoSmithKline; AstraZeneca","keywords":"Fondaparinux; Medicine; Conventional PCI; Percutaneous coronary intervention; Acute coronary syndrome; Myocardial infarction; Bivalirudin; Retrospective cohort study; Anticoagulant; Adjunctive treatment; Heparin; Internal medicine; Emergency medicine; Cardiology; Intensive care medicine; Thrombosis","score_opus":0.049389713624564485,"score_gpt":0.3247635009431197,"score_spread":0.2753737873185552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606920147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565285,0.0027779357,0.00004406886,0.00016317422,0.00005962551,0.0011617934,0.00003379773,0.000014873798,0.000091887145],"genre_scores_gemma":[0.9959929,0.0028774412,0.00030977413,0.00015420651,0.00006935158,0.0000016221453,0.00006248875,0.000055874614,0.0004763153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975296,0.0007481393,0.00047852925,0.00026561305,0.0007959844,0.00018213161],"domain_scores_gemma":[0.99841136,0.00004742534,0.00048466824,0.0005354681,0.000424975,0.000096093536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009392698,0.00022237688,0.00079958147,0.00012975767,0.00021840588,0.000036907248,0.00017162284,0.000024617162,0.00026144888],"category_scores_gemma":[0.000043083335,0.00013421063,0.00060094235,0.00012982397,0.00018354192,0.00044039555,0.00006328703,0.0002253514,0.000011424094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055732783,0.0001422099,0.97984016,0.000110204455,0.0055311983,0.0010643275,0.00013005688,0.0002026321,0.0010764741,0.0000011279291,0.00014000536,0.006188311],"study_design_scores_gemma":[0.00871879,0.0021855703,0.9820761,0.0012187463,0.0013540698,0.0029551582,0.00000987957,0.00010911029,0.00018848642,0.0000010618676,0.0010330098,0.0001499941],"about_ca_topic_score_codex":0.00002560689,"about_ca_topic_score_gemma":0.0000020485838,"teacher_disagreement_score":0.006038317,"about_ca_system_score_codex":0.0001379264,"about_ca_system_score_gemma":0.00003185937,"threshold_uncertainty_score":0.54729503},"labels":[],"label_agreement":null},{"id":"W2762356752","doi":"10.1093/ehjcvp/pvx027","title":"Adherence to guidelines and registry data","year":2017,"lang":"en","type":"editorial","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Data science; Computer science","score_opus":0.14448647742241238,"score_gpt":0.41520994606218287,"score_spread":0.2707234686397705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762356752","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006303533,0.1157444,0.002761519,0.0030767291,0.8554561,0.0015311149,0.00052239373,0.00020735977,0.020070007],"genre_scores_gemma":[0.00009870989,0.057908747,0.00868101,0.0021119916,0.9177221,0.0000098901455,0.0002626479,0.00035465468,0.012850242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940718,0.000604288,0.0009778177,0.0012932186,0.0024138077,0.000639076],"domain_scores_gemma":[0.9930612,0.00013230929,0.0004589431,0.004625713,0.00087584293,0.00084600423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0062184203,0.0007166006,0.001570689,0.00026977118,0.0004405137,0.00057461596,0.0019820833,0.00023271251,0.00018498798],"category_scores_gemma":[0.0019699954,0.00062190084,0.0010929062,0.000118184864,0.00014995963,0.00029534035,0.0011249637,0.0022276172,0.0003055856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022476248,0.000032608335,0.000049701866,0.00016900492,0.005542564,0.0025067157,0.000050617906,0.000010606796,0.0012600363,8.2506645e-8,0.9235526,0.06660072],"study_design_scores_gemma":[0.0038264927,0.000290635,0.00011881237,0.0011223523,0.001951137,0.0018337177,0.00002174862,0.000025489866,0.00018267448,8.8863857e-7,0.9900608,0.0005652468],"about_ca_topic_score_codex":0.000043477372,"about_ca_topic_score_gemma":7.359336e-7,"teacher_disagreement_score":0.06650822,"about_ca_system_score_codex":0.00014047767,"about_ca_system_score_gemma":0.0004561882,"threshold_uncertainty_score":0.99962324},"labels":[],"label_agreement":null},{"id":"W2884349663","doi":"10.1093/ehjcvp/pvy022","title":"A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation","year":2018,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Institut de Recherches Servier; National Heart Foundation of Australia","keywords":"Paroxysmal atrial fibrillation; Double blind; Atrial fibrillation; Medicine; Placebo; Cardiology; Internal medicine; Randomized controlled trial; Anesthesia; Pathology","score_opus":0.06987462197510609,"score_gpt":0.3671342761983882,"score_spread":0.2972596542232821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884349663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865623,0.0022618459,0.000928577,0.000544692,0.0012581093,0.0068303496,8.509711e-7,0.00003896365,0.0015742861],"genre_scores_gemma":[0.98551244,0.0004340309,0.00037168388,0.00014862102,0.013294909,0.0000043321447,0.000008150166,0.000075324344,0.00015049434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941867,0.0029007874,0.0011262468,0.00030139778,0.0011481869,0.00033671004],"domain_scores_gemma":[0.9980001,0.0006109128,0.00049124775,0.0004044691,0.00035480407,0.00013847742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076344665,0.00030053136,0.0015663797,0.00033551015,0.0002625214,0.00016068047,0.0001558343,0.000052229232,0.00017802454],"category_scores_gemma":[0.0002393322,0.00017070552,0.002932365,0.00044885275,0.00021422213,0.00029928848,0.000035507433,0.00036036703,0.000032341657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9671906,0.000026067482,0.018452557,0.000014954341,0.0049192156,0.000016048574,0.00025203126,0.00238427,0.00006078326,0.000007204279,0.00010816007,0.0065680756],"study_design_scores_gemma":[0.96327335,0.0005793036,0.013769112,0.000090843736,0.0018155547,0.000031809323,0.000021290238,0.0003192356,0.0001285771,0.0000043058126,0.019778192,0.0001884211],"about_ca_topic_score_codex":0.0000108574495,"about_ca_topic_score_gemma":3.877717e-7,"teacher_disagreement_score":0.019670032,"about_ca_system_score_codex":0.00006830791,"about_ca_system_score_gemma":0.00011754526,"threshold_uncertainty_score":0.69611686},"labels":[],"label_agreement":null},{"id":"W2884828582","doi":"10.1093/ehjcvp/pvy025","title":"Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1","year":2018,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer","keywords":"Rivaroxaban; Medicine; Atrial fibrillation; Warfarin; Hazard ratio; Internal medicine; Propensity score matching; Stroke (engine); CHA2DS2–VASc score; Interquartile range; Cardiology; Anticoagulant; Embolism; Confidence interval; Ischemic stroke","score_opus":0.02510891571443276,"score_gpt":0.30330153208183214,"score_spread":0.2781926163673994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884828582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951239,0.0016448486,0.0011389569,0.000077098965,0.00035298165,0.0012439926,0.00000550379,0.000019930221,0.00039276917],"genre_scores_gemma":[0.9969304,0.0013812396,0.0003914986,0.000032833374,0.0011404178,4.4473407e-7,0.000011070464,0.00007299439,0.000039058596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997096,0.0008777863,0.0007365878,0.0003185533,0.00071084977,0.00026021674],"domain_scores_gemma":[0.99881357,0.00010537776,0.0002859654,0.00032920932,0.00031829329,0.00014759928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026854435,0.00026205915,0.0009714522,0.0003797301,0.00011380318,0.000023344934,0.000096002244,0.000058714613,0.00007140316],"category_scores_gemma":[0.000049756458,0.00020676109,0.00091792183,0.00049286755,0.00016240812,0.00020986487,0.00005100426,0.00024638322,0.000010023311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006375488,0.000023543693,0.9460505,0.00022782829,0.0038656776,0.000041324718,0.0007243481,0.0025249391,0.007214389,0.000004761007,0.00004083714,0.03290631],"study_design_scores_gemma":[0.027190812,0.0010585529,0.95664513,0.00052998896,0.00056977663,0.000066250686,0.000020310235,0.00037267062,0.0055110343,0.000008079545,0.007813063,0.00021430304],"about_ca_topic_score_codex":0.00002797982,"about_ca_topic_score_gemma":4.653431e-7,"teacher_disagreement_score":0.032692008,"about_ca_system_score_codex":0.00006459727,"about_ca_system_score_gemma":0.00005236909,"threshold_uncertainty_score":0.8431473},"labels":[],"label_agreement":null},{"id":"W2911330885","doi":"10.1093/ehjcvp/pvz004","title":"Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ticagrelor; Pharmacodynamics; Open label; Myocardial infarction; Medicine; Pharmacology; Pharmacokinetics; Randomized controlled trial; Platelet; Anesthesia; Cardiology; Internal medicine; Clopidogrel","score_opus":0.01236013469327582,"score_gpt":0.2793098667455458,"score_spread":0.26694973205227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911330885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771037,0.013005172,0.0010898897,0.00019757569,0.0005438681,0.007225774,0.000035675253,0.00007984391,0.0007184797],"genre_scores_gemma":[0.9864913,0.010890497,0.00031108054,0.0010741488,0.0006510836,0.0001615289,0.000010917298,0.00021479624,0.00019460123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99243206,0.0035316504,0.0010386229,0.0008115246,0.001506663,0.00067949336],"domain_scores_gemma":[0.9977751,0.0001612506,0.00037557664,0.0006318587,0.00056218135,0.0004940762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047981096,0.0006931291,0.0031439897,0.0003926789,0.00022215875,0.00024271995,0.00025717498,0.00008034554,0.0005606796],"category_scores_gemma":[0.000037467,0.0005010275,0.0019936827,0.00047019988,0.0003100431,0.0007123427,0.00009578413,0.0009844138,0.00005627128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86245614,0.0014039978,0.0027094935,0.00013062799,0.047943708,0.0026157338,0.0011533786,0.00045468152,0.036399834,0.000003675854,0.00022628487,0.04450243],"study_design_scores_gemma":[0.9395758,0.005501529,0.017069163,0.00051227474,0.0075072017,0.004678435,0.00017222374,0.000383512,0.005494266,0.00001412621,0.018289028,0.00080244185],"about_ca_topic_score_codex":0.000024494098,"about_ca_topic_score_gemma":4.6849783e-7,"teacher_disagreement_score":0.07711964,"about_ca_system_score_codex":0.00017055082,"about_ca_system_score_gemma":0.0002111169,"threshold_uncertainty_score":0.9997441},"labels":[],"label_agreement":null},{"id":"W2924598001","doi":"10.1093/ehjcvp/pvz013","title":"External applicability of the COMPASS trial: the Western Denmark Heart Registry","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Aarhus Universitetshospital","keywords":"Compass; Medicine; Geography; Cartography","score_opus":0.030462027017349503,"score_gpt":0.30369431096325766,"score_spread":0.27323228394590815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924598001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563813,0.035658654,0.0010186997,0.0015205664,0.0012939067,0.0020228238,0.000011321551,0.000053366504,0.0020393163],"genre_scores_gemma":[0.99037564,0.0025402736,0.00013667336,0.0038441906,0.0020677107,0.000017187233,0.0000019163117,0.00012324878,0.0008931477],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99346495,0.0031526757,0.00078611873,0.00048425698,0.0016247103,0.0004873041],"domain_scores_gemma":[0.99695146,0.00014187378,0.00025974962,0.0020975487,0.00025014154,0.00029919695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049301055,0.0003894041,0.0011199886,0.00007133519,0.000354085,0.00011358114,0.0007344535,0.00007296118,0.00044751167],"category_scores_gemma":[0.000040742587,0.00022002695,0.0064434973,0.00035555515,0.00033046448,0.00014550313,0.000110944165,0.0010641397,0.0002476814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08616958,0.0031423306,0.45495984,0.0010450631,0.054676194,0.0009809398,0.0018915465,0.0060628364,0.2203677,0.000064449545,0.05867478,0.11196475],"study_design_scores_gemma":[0.044954192,0.00033452443,0.14137743,0.0002622946,0.001113875,0.0053643542,0.00010434764,0.000028939601,0.009029827,0.000019865658,0.7970962,0.00031415187],"about_ca_topic_score_codex":0.0000121764515,"about_ca_topic_score_gemma":2.2188179e-7,"teacher_disagreement_score":0.73842144,"about_ca_system_score_codex":0.000080585356,"about_ca_system_score_gemma":0.00019232392,"threshold_uncertainty_score":0.89724386},"labels":[],"label_agreement":null},{"id":"W2979778936","doi":"10.1093/ehjcvp/pvz048","title":"P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta","funders":"","keywords":"Medicine; Acute coronary syndrome; Internal medicine; Myocardial infarction; Hazard ratio; Prasugrel; Renal function; Kidney disease; Ticagrelor; Clinical endpoint; Cardiology; Confidence interval; Clinical trial","score_opus":0.012632708451280393,"score_gpt":0.24462247632410378,"score_spread":0.23198976787282338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979778936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981233,0.016878685,0.00027189188,0.00014815918,0.0002780303,0.0009577129,0.000030531977,0.00006436764,0.00013762942],"genre_scores_gemma":[0.9937805,0.0039435476,0.00021144775,0.0013094052,0.00043664157,0.000010638999,0.00010357348,0.00011385359,0.00009038104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546564,0.001724328,0.00049355073,0.0006604326,0.0012027822,0.00045324877],"domain_scores_gemma":[0.9983725,0.00006541937,0.00013649915,0.00085974194,0.00018890788,0.00037692892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016570204,0.00041775298,0.0010263288,0.00031083077,0.00026244868,0.00015553864,0.00021739122,0.000069292415,0.00036883645],"category_scores_gemma":[0.000008405894,0.0002669005,0.001620052,0.0008552561,0.00012973869,0.00047487035,0.000047101516,0.0007410478,0.000050331837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026245841,0.00034160045,0.92596775,0.000021102209,0.044559497,0.0027261216,0.0005701541,0.0026104024,0.0009171209,8.7656684e-7,0.00035960908,0.01930119],"study_design_scores_gemma":[0.014010198,0.00089751085,0.9535021,0.00017731667,0.0064113946,0.0024917093,0.00017979398,0.00018883697,0.00020191433,0.0000029684056,0.021552488,0.0003837526],"about_ca_topic_score_codex":0.000043836986,"about_ca_topic_score_gemma":0.000004457061,"teacher_disagreement_score":0.038148105,"about_ca_system_score_codex":0.000100935096,"about_ca_system_score_gemma":0.0001071553,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W2979957865","doi":"10.1093/ehjcvp/pvz056","title":"Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Japanese Association of Cardiovascular Intervention and Therapeutics","keywords":"Prasugrel; Medicine; Clopidogrel; Percutaneous coronary intervention; Acute coronary syndrome; Internal medicine; Cardiology; Emergency medicine; Aspirin; Myocardial infarction","score_opus":0.014256960035437664,"score_gpt":0.30828563454790875,"score_spread":0.2940286745124711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979957865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270487,0.004371512,0.000011653389,0.00004820063,0.0003077206,0.0023560105,0.00006192089,0.00002839116,0.0001097251],"genre_scores_gemma":[0.99722326,0.0023096346,0.000078772384,0.00008014935,0.0000655549,0.0000138880905,0.000035788737,0.00014118972,0.000051789855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448043,0.001679813,0.0012053633,0.00059647695,0.0015563014,0.00048162133],"domain_scores_gemma":[0.9981793,0.00008945774,0.00039404127,0.0008052926,0.000304415,0.00022748506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002030621,0.00051316724,0.0017839975,0.00077366,0.000054018485,0.000033753742,0.00030241846,0.00008571754,0.00016703765],"category_scores_gemma":[0.00005084861,0.00040110026,0.0024411767,0.0005990689,0.00012034323,0.00033193725,0.000053176194,0.00086425396,0.000016684697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0154197,0.0050721485,0.9434968,0.00012024071,0.011807798,0.006276321,0.0013803369,0.002783901,0.0007893259,6.807149e-7,0.000047006575,0.012805691],"study_design_scores_gemma":[0.03898065,0.011984235,0.94345003,0.0010752643,0.0005663247,0.0027452814,0.00054580026,0.000024450608,0.00009907055,0.0000030789843,0.00015599316,0.00036984353],"about_ca_topic_score_codex":0.0000880214,"about_ca_topic_score_gemma":0.0000051492484,"teacher_disagreement_score":0.023560952,"about_ca_system_score_codex":0.0004427893,"about_ca_system_score_gemma":0.0002744644,"threshold_uncertainty_score":0.9998441},"labels":[],"label_agreement":null},{"id":"W2995308085","doi":"10.1093/ehjcvp/pvz052","title":"Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center","funders":"Daiichi Sankyo Europe; Medicure; Medicines Company; Amgen; Biosensors International Group; AstraZeneca","keywords":"Medicine; Internal medicine; Ticagrelor; Percutaneous coronary intervention; COPD; Hazard ratio; Conventional PCI; Myocardial infarction; Clinical endpoint; Cardiology; Randomized controlled trial; Confidence interval","score_opus":0.03449033274264302,"score_gpt":0.3542081879002301,"score_spread":0.3197178551575871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995308085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822627,0.014489489,0.000032620857,0.00008233403,0.0003831978,0.0024277566,0.000021811138,0.00002051374,0.00027961135],"genre_scores_gemma":[0.9920215,0.0073166643,0.000014433516,0.0002380059,0.00030002242,0.000011443293,0.000022420312,0.00005279381,0.000022696197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99149513,0.005920844,0.0009955398,0.0004373546,0.00078328437,0.00036786398],"domain_scores_gemma":[0.99852335,0.0004822496,0.0001970888,0.00045515038,0.00009286366,0.00024927923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034068453,0.00036207237,0.0015457482,0.00018620757,0.000073511575,0.000043917546,0.00018606053,0.00006796143,0.00011090358],"category_scores_gemma":[0.00017894866,0.00022787291,0.005523641,0.00025104254,0.00026764057,0.00016639082,0.000028840203,0.0006106452,0.00002205403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36311337,0.0015855863,0.58442146,0.00006516862,0.008809666,0.00220671,0.0001757137,0.0010337383,0.00004582931,0.0000038054063,0.000024652669,0.038514297],"study_design_scores_gemma":[0.34389305,0.0017724553,0.65163255,0.0002386931,0.0008986848,0.0009603142,0.000115345276,0.00015978747,0.000003105681,0.000021665926,0.0001308389,0.00017351874],"about_ca_topic_score_codex":0.000031120646,"about_ca_topic_score_gemma":0.0000010941441,"teacher_disagreement_score":0.0672111,"about_ca_system_score_codex":0.00031257546,"about_ca_system_score_gemma":0.00016362924,"threshold_uncertainty_score":0.92923874},"labels":[],"label_agreement":null},{"id":"W2996098367","doi":"10.1093/ehjcvp/pvz076","title":"New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering; Ministry of Education, Culture, Sports, Science and Technology; Vehicle Racing Commemorative Foundation; Bayer; Bristol-Myers Squibb","keywords":"Atrial fibrillation; Internal medicine; Vitamin k; Cardiology; Medicine; Prothrombin time; Vitamin K antagonist; Warfarin","score_opus":0.10883664368840869,"score_gpt":0.3503914368703736,"score_spread":0.24155479318196493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996098367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674017,0.0003172166,0.023306845,0.000676604,0.0041671935,0.0024331058,0.000014497366,0.00009634947,0.0015865024],"genre_scores_gemma":[0.98060644,0.0005849021,0.0051876428,0.00040998813,0.012107143,0.0000012977121,0.00009241478,0.0001334598,0.0008767215],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9965275,0.00060827914,0.00088072533,0.0003980401,0.0012787369,0.0003067001],"domain_scores_gemma":[0.9990549,0.00003984343,0.00022899102,0.0002799289,0.00021882335,0.00017750628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017526977,0.0002822723,0.0005308723,0.00038628528,0.00013894266,0.00017625537,0.00014848143,0.00007288215,0.0007531429],"category_scores_gemma":[0.000090846246,0.0002672108,0.0010212605,0.00026532475,0.000019352558,0.0005034176,0.00004136273,0.00032987038,0.00027424694],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007042131,0.000052848438,0.087213375,0.000037447157,0.0022705293,0.00002756206,0.0005026292,0.6909525,0.15699829,0.000031570322,0.0010733453,0.053797826],"study_design_scores_gemma":[0.050549954,0.002537343,0.065856226,0.0012488167,0.0016887083,0.00033802536,0.00013465782,0.68318796,0.08815335,0.00036447356,0.10396135,0.001979134],"about_ca_topic_score_codex":0.000015136315,"about_ca_topic_score_gemma":4.414617e-7,"teacher_disagreement_score":0.102888,"about_ca_system_score_codex":0.0003416887,"about_ca_system_score_gemma":0.00014466766,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W2996405285","doi":"10.1093/ehjcvp/pvz051","title":"Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study","year":2019,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Biosensors International Group; Medicines Company","keywords":"Bivalirudin; Percutaneous coronary intervention; Post-hoc analysis; Medicine; Adverse effect; Internal medicine; Intervention (counseling); Cardiology; Psychiatry; Myocardial infarction","score_opus":0.05211884419044743,"score_gpt":0.3907562682149411,"score_spread":0.33863742402449365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996405285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334943,0.0022062836,0.00006500789,0.0022868635,0.0006144853,0.0011739703,0.00006374995,0.000033962024,0.00020624272],"genre_scores_gemma":[0.9950039,0.001994549,0.00006886185,0.0020645915,0.00053195836,0.0000023674045,0.000021509775,0.000048219208,0.00026403935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913792,0.005293516,0.001005572,0.0004144274,0.0015617438,0.000345542],"domain_scores_gemma":[0.99784964,0.00019027811,0.00037125856,0.0005653118,0.00073645305,0.00028707704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007131446,0.00024537626,0.0010549155,0.000319389,0.00018535313,0.000039506762,0.00025456,0.00009114263,0.00032362549],"category_scores_gemma":[0.00022764293,0.00018253645,0.0034630336,0.0009642331,0.0000960706,0.00019043768,0.00016043641,0.0008667381,0.00006936984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010749806,0.00033154877,0.925924,0.000022622029,0.052220218,0.00015588476,0.00039399054,0.00042671565,0.002291357,2.6385493e-7,0.0011392499,0.01601916],"study_design_scores_gemma":[0.006149523,0.0019947544,0.9521306,0.00007567801,0.00848791,0.0007926695,0.0010822214,0.00010292841,0.000038465558,0.000001292829,0.028978683,0.00016523828],"about_ca_topic_score_codex":0.00013501127,"about_ca_topic_score_gemma":0.0000033853953,"teacher_disagreement_score":0.043732308,"about_ca_system_score_codex":0.0004237754,"about_ca_system_score_gemma":0.000099813646,"threshold_uncertainty_score":0.74436206},"labels":[],"label_agreement":null},{"id":"W3006247054","doi":"10.1093/ehjcvp/pvaa010","title":"Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk—an inverse probability of treatment weighted study on 54 872 patients","year":2020,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Vetenskapsrådet","keywords":"Medicine; Myocardial infarction; Statin; Internal medicine; Cardiology; Emergency medicine","score_opus":0.042396250297567196,"score_gpt":0.3070202954930183,"score_spread":0.2646240451954511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006247054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515384,0.00014752617,0.000054430515,0.00009370627,0.00014055111,0.0040249024,0.00023711662,0.00008290631,0.000065008106],"genre_scores_gemma":[0.9972437,0.0006297632,0.0002082429,0.00084049127,0.0007747362,0.00012523825,0.000039480536,0.0001255458,0.0000128234715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915254,0.0049938615,0.0007006475,0.0007745999,0.001515816,0.0004896577],"domain_scores_gemma":[0.9971539,0.000032406064,0.00027312172,0.0011639292,0.00044638055,0.00093027955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020563803,0.00052528025,0.0011477044,0.000117014926,0.00036351243,0.00009210905,0.00019465642,0.00005962735,0.0001633738],"category_scores_gemma":[0.00004617378,0.00032531403,0.0014363312,0.00048424368,0.00008448397,0.00023412188,0.00003551706,0.00049488747,0.000038439586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01187562,0.0071206726,0.8834505,0.000062685554,0.05240923,0.0006356747,0.020797776,0.0012952634,0.0029086613,3.174311e-7,0.000113095964,0.019330466],"study_design_scores_gemma":[0.023603527,0.028708043,0.93718886,0.00008966642,0.003537733,0.00004205251,0.0004854999,0.00008099389,0.0041926694,0.0000015520366,0.0017183486,0.00035106926],"about_ca_topic_score_codex":0.001059358,"about_ca_topic_score_gemma":0.000050811366,"teacher_disagreement_score":0.053738315,"about_ca_system_score_codex":0.0008129468,"about_ca_system_score_gemma":0.00028547697,"threshold_uncertainty_score":0.9999199},"labels":[],"label_agreement":null},{"id":"W3027492459","doi":"10.1093/ehjcvp/pvaa052","title":"Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation","year":2020,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact; Boehringer Ingelheim (Canada)","funders":"","keywords":"Persistence (discontinuity); Medicine; Atrial fibrillation; Intensive care medicine; Internal medicine","score_opus":0.6538836013044301,"score_gpt":0.4957609362226268,"score_spread":0.15812266508180334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027492459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001039992,0.9898328,0.0053944634,0.0011087814,0.0008225322,0.0024637373,0.00001306907,0.00008915562,0.0001714405],"genre_scores_gemma":[0.00022597071,0.9576536,0.031180268,0.0003679736,0.010316259,0.0000031778009,0.00005988853,0.00012948242,0.00006338406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99283403,0.004312725,0.0013616717,0.000546487,0.0005914533,0.00035363383],"domain_scores_gemma":[0.9974666,0.0013283293,0.0004626661,0.00028893465,0.0001736356,0.0002797978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0051408214,0.00046847435,0.0028145537,0.0004066909,0.0003000839,0.00020395748,0.000110765024,0.0001451047,0.00012939861],"category_scores_gemma":[0.001871592,0.00038443084,0.0067169084,0.0004914278,0.000070668,0.00021863086,0.000046914432,0.00066293235,0.000051867366],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010607804,0.000003856356,0.0006929439,0.0020760437,0.0039496915,0.00019845487,0.00018137363,0.0025162403,0.00008399063,0.000048608643,0.00088769535,0.989255],"study_design_scores_gemma":[0.0030398734,0.00015447265,0.00039248474,0.0016709323,0.0038300417,0.0010459814,0.000019337594,0.00072859164,0.00000779383,0.000081046535,0.9886654,0.00036405097],"about_ca_topic_score_codex":0.000002099057,"about_ca_topic_score_gemma":2.1059553e-7,"teacher_disagreement_score":0.98889095,"about_ca_system_score_codex":0.00019729845,"about_ca_system_score_gemma":0.0002895704,"threshold_uncertainty_score":0.99986076},"labels":[],"label_agreement":null},{"id":"W3045745999","doi":"10.1093/ehjcvp/pvaa094","title":"Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists","year":2020,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Atrial fibrillation; Internal medicine; Vitamin k; Cardiology","score_opus":0.039772375883077145,"score_gpt":0.3136338803782939,"score_spread":0.2738615044952168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045745999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479127,0.0016638074,0.0014224305,0.00065357966,0.0002689468,0.0007598281,0.0000158395,0.000047939448,0.00037633177],"genre_scores_gemma":[0.99327135,0.0015278307,0.0014001214,0.00065410417,0.0030136427,1.9466668e-7,0.000031348638,0.00008859748,0.000012786713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967689,0.0010165705,0.00067432947,0.0003289077,0.0009081045,0.00030321346],"domain_scores_gemma":[0.9989058,0.00008386349,0.0003437492,0.00024605068,0.00018857798,0.00023195866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014334627,0.00028324037,0.001021236,0.0002066095,0.00014186827,0.00006495139,0.000109062865,0.000050356517,0.000092266404],"category_scores_gemma":[0.0001405042,0.00022136456,0.0012458886,0.00045925035,0.000043643315,0.00027455864,0.000035033336,0.00042612545,0.000026108886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026052475,0.000011958133,0.9623201,0.00006581475,0.0029094077,0.00013034558,0.00048045666,0.019012513,0.0009501132,3.0908123e-7,0.00038830118,0.011125417],"study_design_scores_gemma":[0.017073931,0.0006241237,0.91329217,0.00013034468,0.00092831894,0.000027292577,0.000027288568,0.0010094619,0.0016403621,9.861564e-7,0.064986594,0.0002590979],"about_ca_topic_score_codex":0.000016753555,"about_ca_topic_score_gemma":2.6404436e-7,"teacher_disagreement_score":0.06459829,"about_ca_system_score_codex":0.000051773834,"about_ca_system_score_gemma":0.00005677805,"threshold_uncertainty_score":0.90269846},"labels":[],"label_agreement":null},{"id":"W3087038991","doi":"10.1093/ehjcvp/pvaa106","title":"PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY","year":2020,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Agence Nationale de la Recherche; Medicines Company; Biosensors International Group; AstraZeneca","keywords":"Dual (grammatical number); Internal medicine; Medicine; Philosophy","score_opus":0.07440001213608693,"score_gpt":0.2866779878047502,"score_spread":0.21227797566866324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087038991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659633,0.029634375,0.001311721,0.0007574075,0.0005322135,0.0013256315,0.00016382217,0.0001005454,0.00021098068],"genre_scores_gemma":[0.9827936,0.010579707,0.00029777753,0.0033711034,0.002759652,0.000014055897,0.00004815139,0.00011848295,0.000017443244],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962471,0.0011844416,0.00059869484,0.0006281176,0.000909142,0.0004324925],"domain_scores_gemma":[0.9986695,0.0001698324,0.00016771289,0.00039639618,0.00016425943,0.00043227422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009408435,0.00040882648,0.00079619524,0.00008134672,0.00041455036,0.00015117724,0.00018519195,0.00008731617,0.000053291744],"category_scores_gemma":[0.00018405746,0.00027445675,0.0014446398,0.00036802609,0.00015690243,0.00028044946,0.000040441333,0.0006412545,0.000028083361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060194604,0.0018542719,0.5309076,0.000381478,0.04200417,0.002983598,0.008007542,0.008633144,0.008793591,0.000018653753,0.04128718,0.29493418],"study_design_scores_gemma":[0.07219477,0.005478413,0.39647517,0.0012592816,0.0037094525,0.0009763367,0.0011963287,0.0013731869,0.0053249523,0.00007571863,0.5109427,0.000993695],"about_ca_topic_score_codex":0.00001631656,"about_ca_topic_score_gemma":0.0000011699547,"teacher_disagreement_score":0.4696555,"about_ca_system_score_codex":0.00013939846,"about_ca_system_score_gemma":0.000076281016,"threshold_uncertainty_score":0.99997073},"labels":[],"label_agreement":null},{"id":"W3087528042","doi":"10.1093/ehjcvp/pvaa110","title":"Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"British Heart Foundation; Medicines Company; AstraZeneca","keywords":"Medicine; Ticagrelor; Percutaneous coronary intervention; Internal medicine; Conventional PCI; Hazard ratio; Aspirin; Myocardial infarction; Clinical endpoint; White blood cell; Randomized controlled trial; Confidence interval; Cardiology; Surgery","score_opus":0.04125119407432932,"score_gpt":0.32685569064297965,"score_spread":0.28560449656865033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087528042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936922,0.003679844,0.000029825944,0.00044137417,0.00029387418,0.0014484087,0.00011545034,0.00005217009,0.00024680918],"genre_scores_gemma":[0.9955593,0.00067052693,0.00020930423,0.0026560512,0.0007486568,0.000013988075,0.000021449247,0.000110437824,0.0000103058555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943976,0.0024425045,0.0011372516,0.00053322135,0.0011215576,0.00036790376],"domain_scores_gemma":[0.99812406,0.00014796421,0.00028141658,0.0007406383,0.00023433182,0.00047156354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007718392,0.00047649117,0.0010792429,0.00008561795,0.00012788677,0.00005967646,0.00043645792,0.000090578586,0.0004353009],"category_scores_gemma":[0.00006465575,0.00028397446,0.003322151,0.00029927978,0.00025628033,0.00013392301,0.00007305578,0.00072757,0.000041990403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1402337,0.0018104515,0.8385326,0.000023390938,0.011625725,0.0028557682,0.00059430767,0.0001293045,0.000075988595,1.1931134e-7,0.00062584376,0.0034927544],"study_design_scores_gemma":[0.1326598,0.008336369,0.8548588,0.00018135546,0.0014152097,0.00019467509,0.00006155744,0.000027073527,0.000111432724,0.000002219604,0.0018702812,0.00028120453],"about_ca_topic_score_codex":0.00002461272,"about_ca_topic_score_gemma":0.0000016680264,"teacher_disagreement_score":0.01632617,"about_ca_system_score_codex":0.00020059544,"about_ca_system_score_gemma":0.00014417915,"threshold_uncertainty_score":0.99996126},"labels":[],"label_agreement":null},{"id":"W3091209026","doi":"10.1093/ehjcvp/pvaa118","title":"REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","year":2020,"lang":"en","type":"letter","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Interim; Interim analysis; Environmental science; Medicine; Political science; Clinical trial; Internal medicine; Law","score_opus":0.6569511246349635,"score_gpt":0.5574347546978977,"score_spread":0.09951636993706581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091209026","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006259291,0.014181053,0.0066748075,0.957094,0.009228675,0.0020981673,0.0022547632,0.00025895634,0.0019502639],"genre_scores_gemma":[0.031437792,0.0067851488,0.010839534,0.87970674,0.06713358,0.000018527939,0.0017888609,0.000978517,0.0013112929],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98641646,0.006284004,0.0020419064,0.001470683,0.0024517253,0.0013352027],"domain_scores_gemma":[0.9951444,0.0002645657,0.00066173525,0.0026042713,0.000588653,0.0007363388],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0054856846,0.00078094454,0.0017898118,0.00054366124,0.0005411985,0.00065639836,0.0029232204,0.00025903984,0.00034372247],"category_scores_gemma":[0.0005372343,0.0007173951,0.0020855975,0.0008042023,0.0002120554,0.0007673029,0.00075007766,0.0058184783,0.0004317466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004595373,0.000074196716,0.000007979976,0.00030334247,0.002941347,0.0018816518,0.0016377958,0.0004865839,0.04834489,3.7338918e-8,0.9043846,0.03534219],"study_design_scores_gemma":[0.0040410534,0.00088773825,0.0004256247,0.0008007221,0.00036013703,0.0007783474,0.00009992016,0.00036456436,0.019257136,0.0000050524786,0.9723546,0.0006251283],"about_ca_topic_score_codex":0.000117821284,"about_ca_topic_score_gemma":0.000004049781,"teacher_disagreement_score":0.07738728,"about_ca_system_score_codex":0.00030613333,"about_ca_system_score_gemma":0.00024705855,"threshold_uncertainty_score":0.9995277},"labels":[],"label_agreement":null},{"id":"W3115800539","doi":"10.1093/ehjcvp/pvaa140","title":"Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial","year":2020,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Diabetes mellitus; Internal medicine; Hazard ratio; Insulin; Stroke (engine); Atrial fibrillation; Proportional hazards model; Myocardial infarction; Risk factor; Cardiology; Endocrinology; Confidence interval","score_opus":0.05614470506966717,"score_gpt":0.32408622273162785,"score_spread":0.26794151766196067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115800539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468815,0.0021523694,0.0006238386,0.00012701875,0.00032590408,0.001953429,0.00009287632,0.000022388314,0.0000140444645],"genre_scores_gemma":[0.99792737,0.00030495334,0.00025838136,0.00010604439,0.0013096391,9.3579786e-7,0.000025308362,0.000060901748,0.0000064511705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99589765,0.0015685643,0.0008388485,0.00036544944,0.00106969,0.00025979933],"domain_scores_gemma":[0.99840957,0.000101577476,0.00043853815,0.0005338597,0.00030978493,0.00020666562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014878337,0.0002599831,0.0013757466,0.00028803013,0.00013538497,0.000015597401,0.00019013438,0.000052774907,0.000086659],"category_scores_gemma":[0.00019984855,0.00017767977,0.0062816567,0.0010069448,0.00005882754,0.00018778624,0.00004362958,0.0002157999,0.0000031733894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011182133,0.000027087608,0.85614127,0.00004992409,0.03577148,0.000004380039,0.00031286458,0.09179618,0.0007459412,4.794506e-7,0.000006887593,0.0039613973],"study_design_scores_gemma":[0.073762454,0.00095260603,0.89971566,0.000042526477,0.012817652,0.0000022467898,0.000028198257,0.0021857237,0.0021204995,0.0000023835098,0.008163108,0.00020692455],"about_ca_topic_score_codex":0.000024133691,"about_ca_topic_score_gemma":0.0000019185497,"teacher_disagreement_score":0.08961046,"about_ca_system_score_codex":0.000056341298,"about_ca_system_score_gemma":0.0000720597,"threshold_uncertainty_score":0.7245571},"labels":[],"label_agreement":null},{"id":"W3125008730","doi":"10.1093/ehjcvp/pvab005","title":"The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer","year":2021,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Hamilton Health Sciences; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Goserelin; Adverse effect; Internal medicine; Gonadotropin-releasing hormone antagonist; Hormone antagonist; Testosterone (patch); Gonadotropin-releasing hormone; Androgen deprivation therapy; Oncology; Agonist; Endocrinology; Antagonist; Hormone; Cancer; Receptor; Luteinizing hormone","score_opus":0.043209260730617864,"score_gpt":0.3677541840522094,"score_spread":0.3245449233215915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125008730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007424652,0.99514395,0.000037314927,0.0001546617,0.0003987721,0.0030022608,0.000023253417,0.000037169095,0.00046014966],"genre_scores_gemma":[0.00020417638,0.9971191,0.00013977804,0.00006586921,0.001254228,0.0001739504,0.000032963388,0.00036709112,0.00064283767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99090666,0.004313751,0.0011057268,0.0007835203,0.0018933901,0.0009969565],"domain_scores_gemma":[0.9972775,0.00025593292,0.00035170652,0.0012103589,0.00045611148,0.00044836244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002469816,0.0008442157,0.004262487,0.00039921704,0.00043497916,0.0002092897,0.00043405726,0.00012880191,0.000021494376],"category_scores_gemma":[0.00004765607,0.0004741345,0.006203344,0.0010848048,0.00031670986,0.00014276219,0.0001081471,0.0020061587,0.000017880306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053075585,0.00016341412,0.0000721196,0.007940014,0.04393846,0.010060731,0.00023633691,0.000107045096,0.00022130221,0.000001035223,0.0018621559,0.9348666],"study_design_scores_gemma":[0.008148444,0.00039691545,0.0005585957,0.020850506,0.0068706553,0.0044553783,0.00003656372,0.000004975948,0.0003114462,7.833097e-7,0.95789087,0.00047488592],"about_ca_topic_score_codex":0.000092437265,"about_ca_topic_score_gemma":0.0000010244254,"teacher_disagreement_score":0.9560287,"about_ca_system_score_codex":0.0007515095,"about_ca_system_score_gemma":0.0016184162,"threshold_uncertainty_score":0.99977106},"labels":[],"label_agreement":null},{"id":"W3131158196","doi":"10.1093/ehjcvp/pvab016","title":"Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; St. Boniface Hospital; Canadian VIGOUR Centre; University of Alberta","funders":"Canadian Institutes of Health Research; University Hospital Foundation; Heart and Stroke Foundation of Canada","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Internal medicine; Breast cancer; Cardiology; Natriuretic peptide; Brain natriuretic peptide; Oncology; Cardiac function curve; Troponin; Cancer; Chemotherapy; Heart failure; Myocardial infarction","score_opus":0.032480192444066816,"score_gpt":0.2941583417594079,"score_spread":0.2616781493153411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131158196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605626,0.034751724,0.0008466378,0.0002305385,0.00080914743,0.00072342233,0.00008991631,0.000033314675,0.0019526905],"genre_scores_gemma":[0.98806745,0.009913349,0.00023772575,0.0005026618,0.0010822662,0.000007263835,0.000025896401,0.00008870193,0.00007469792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99473035,0.0022923846,0.0009295563,0.00047372738,0.001187994,0.0003860001],"domain_scores_gemma":[0.99781954,0.00015329696,0.00032567975,0.0008834375,0.00053790526,0.0002801103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029150895,0.0003497385,0.0022812362,0.00051634316,0.00022719898,0.00005925432,0.00019596651,0.00010869716,0.00010703538],"category_scores_gemma":[0.0001479856,0.00028046774,0.0063994727,0.0021480531,0.00024222037,0.00014861964,0.000078430385,0.0008046222,0.0000026742591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019448511,0.00017216532,0.0050165714,0.00015525395,0.068814814,0.00011307671,0.0010969047,0.00059689675,0.8812953,0.000010732418,0.0002879494,0.04049546],"study_design_scores_gemma":[0.04968877,0.00025231694,0.17103197,0.00028896943,0.026720656,0.0014087383,0.00064753735,0.0003237591,0.6827849,0.00001430995,0.06627971,0.00055837404],"about_ca_topic_score_codex":0.000021596989,"about_ca_topic_score_gemma":9.939982e-7,"teacher_disagreement_score":0.19851044,"about_ca_system_score_codex":0.00009709723,"about_ca_system_score_gemma":0.0004033054,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W3165711010","doi":"10.1093/ehjcvp/pvab022","title":"Vericiguat in the management of heart failure with reduced ejection fraction","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University Health Centre","funders":"","keywords":"Heart failure; Cyclic guanosine monophosphate; Ejection fraction; Nitric oxide; Internal medicine; Cardiology; Vasodilation; Medicine; Fibrosis; Pharmacology; Chemistry","score_opus":0.028326158132391612,"score_gpt":0.30068080396283076,"score_spread":0.27235464583043917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165711010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585533,0.009509601,0.0033473049,0.015935082,0.00052932615,0.0014956059,0.0000022666115,0.00008753756,0.010539941],"genre_scores_gemma":[0.9810895,0.0041848305,0.011610904,0.0019496878,0.00062577595,0.00002089506,0.000012188537,0.00007546905,0.00043077275],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972629,0.001003256,0.0003587539,0.00029165923,0.00080174266,0.00028170217],"domain_scores_gemma":[0.99916613,0.000025079607,0.000073226,0.0004893337,0.00014100785,0.00010522407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017000856,0.00020809322,0.00044461616,0.00016110053,0.00014071308,0.00006268899,0.000092953516,0.000026883714,0.00023348782],"category_scores_gemma":[0.00000440869,0.00013822867,0.0006787004,0.00058636087,0.000037616985,0.00016324039,0.000021681662,0.00042704787,0.00006361329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004677766,0.006373377,0.05987154,0.0017599097,0.061764143,0.042401254,0.0045307004,0.007039759,0.34736314,0.00024404272,0.27687955,0.18709482],"study_design_scores_gemma":[0.0061119515,0.00032528854,0.04813873,0.00032866458,0.0009518246,0.0038093668,0.0013079554,0.000020540632,0.01494428,0.0000062526933,0.92388386,0.00017128674],"about_ca_topic_score_codex":0.000009516637,"about_ca_topic_score_gemma":0.0000011564259,"teacher_disagreement_score":0.6470043,"about_ca_system_score_codex":0.00011134829,"about_ca_system_score_gemma":0.000050245926,"threshold_uncertainty_score":0.5636802},"labels":[],"label_agreement":null},{"id":"W3166286424","doi":"10.1093/ehjcvp/pvab044","title":"Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials","year":2021,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research; Deutsche Herzstiftung; Stockholms Läns Landsting; Hjärt-Lungfonden","keywords":"Atrial fibrillation; Randomized controlled trial; Medicine; Meta-analysis; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.23153052482020123,"score_gpt":0.42434109054281155,"score_spread":0.19281056572261032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166286424","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034987956,0.98953784,0.00010625687,0.0001583454,0.0001318824,0.009916069,0.000039157385,0.000022135484,0.00005335579],"genre_scores_gemma":[0.00003275852,0.9982814,0.00026938692,0.00030502342,0.0006967785,0.000010577071,0.0001288463,0.00012609157,0.00014911334],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9684457,0.024892643,0.004529066,0.0005481865,0.0013041846,0.00028021276],"domain_scores_gemma":[0.9940777,0.0019172515,0.002516419,0.00080260565,0.0004941076,0.00019194567],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.027530925,0.000751747,0.045895737,0.0012112764,0.00008588271,0.00012390211,0.00017123493,0.00010392711,0.00070470275],"category_scores_gemma":[0.0010304671,0.00039810373,0.049803127,0.0018820742,0.00008239436,0.00015176632,0.00004513759,0.00045868708,0.000008369396],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021688123,0.000009783737,0.00008038214,0.11334724,0.8703814,0.000080934886,0.000033328535,0.00010398708,8.500176e-8,0.000002524777,0.000086594766,0.01370489],"study_design_scores_gemma":[0.048084736,0.00008329383,0.00002715541,0.016682386,0.73871094,0.00009416965,0.000002071872,0.0000029677053,2.703247e-7,3.536352e-7,0.19603275,0.0002789207],"about_ca_topic_score_codex":0.0000031972424,"about_ca_topic_score_gemma":1.008635e-7,"teacher_disagreement_score":0.19594616,"about_ca_system_score_codex":0.00006366357,"about_ca_system_score_gemma":0.00014273314,"threshold_uncertainty_score":0.99984705},"labels":[],"label_agreement":null},{"id":"W3174871823","doi":"10.1093/ehjcvp/pvab050","title":"Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Bayer","keywords":"Rivaroxaban; Medicine; Polypharmacy; Aspirin; Concomitant; Myocardial infarction; Internal medicine; Hazard ratio; Stroke (engine); Warfarin; Coronary artery disease; Regimen; Comorbidity; Clopidogrel; Atrial fibrillation; Confidence interval","score_opus":0.053364768004334776,"score_gpt":0.3484500248329785,"score_spread":0.2950852568286437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174871823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992051,0.0036359907,0.0006785878,0.0020282487,0.00038546327,0.0009023219,0.000048786133,0.00004712533,0.00022244609],"genre_scores_gemma":[0.9878567,0.0019131068,0.00071063195,0.00717215,0.002023747,0.000012619245,0.00012901529,0.00011426767,0.00006774958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927764,0.0040493403,0.0005870648,0.00060809305,0.0014692049,0.00050988205],"domain_scores_gemma":[0.99781805,0.00016538789,0.000121576944,0.00085204,0.00044236722,0.00060057355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002498308,0.0003423926,0.0010234666,0.0003265483,0.00033039317,0.0002862187,0.00026164198,0.000049194365,0.0005408151],"category_scores_gemma":[0.00006186926,0.00023685017,0.001196788,0.0010793793,0.00016868085,0.00031879096,0.000101863734,0.0012759833,0.000042476797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09150722,0.003203506,0.6849091,0.000055421635,0.09136988,0.008549586,0.0028846837,0.012164581,0.01035215,0.0000043243435,0.009889018,0.085110515],"study_design_scores_gemma":[0.1595198,0.00057015935,0.693687,0.00006956889,0.0028405315,0.00029526657,0.00015743535,0.0016459306,0.0016415665,0.000002090352,0.13918747,0.00038314812],"about_ca_topic_score_codex":0.0003164828,"about_ca_topic_score_gemma":0.000008676289,"teacher_disagreement_score":0.12929845,"about_ca_system_score_codex":0.00019637807,"about_ca_system_score_gemma":0.000245815,"threshold_uncertainty_score":0.965847},"labels":[],"label_agreement":null},{"id":"W3177890216","doi":"10.1093/ehjcvp/pvab052","title":"An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto","funders":"","keywords":"Rheumatoid arthritis; Medicine; Internal medicine; Audit; Blood pressure; Disease","score_opus":0.014358905205050836,"score_gpt":0.2599488636948468,"score_spread":0.24558995848979598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177890216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97174776,0.026883554,0.00005686629,0.00039680148,0.0002292675,0.00024637638,0.000059505976,0.000009910026,0.00036995756],"genre_scores_gemma":[0.8322418,0.16662653,0.000788157,0.0001997637,0.000079992315,0.0000016203954,0.000019830351,0.000029962212,0.0000123662185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975103,0.00062129606,0.0004877578,0.00025487095,0.00093425805,0.00019151013],"domain_scores_gemma":[0.9989045,0.00004169855,0.00013005726,0.00041608742,0.00035739248,0.00015024068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009516502,0.00014452022,0.00042896473,0.00010057118,0.00009686881,0.000050365732,0.00015669287,0.00002168633,0.00008596856],"category_scores_gemma":[0.000026721022,0.000099955665,0.00026077402,0.00016603254,0.00014457687,0.00021108358,0.00005434903,0.00027933484,0.00000307248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009847249,0.0014310164,0.7312373,0.00015493875,0.014409385,0.0024307687,0.0027989603,0.0010375459,0.022114493,0.0000795458,0.001820132,0.21263869],"study_design_scores_gemma":[0.02763042,0.0002523659,0.88607323,0.0021414936,0.000028990426,0.0005298974,0.00026977624,0.000047633657,0.0077227363,0.000019161096,0.07513739,0.00014688047],"about_ca_topic_score_codex":0.000032897166,"about_ca_topic_score_gemma":0.0000030349445,"teacher_disagreement_score":0.21249181,"about_ca_system_score_codex":0.000035777855,"about_ca_system_score_gemma":0.0000797813,"threshold_uncertainty_score":0.40760738},"labels":[],"label_agreement":null},{"id":"W3205764067","doi":"10.1093/ehjcvp/pvab076","title":"Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC–EHRA EORP AF Long-Term General Registry","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Abbott Vascular; Novartis Pharma; Bristol-Myers Squibb Canada; Servier; Vifor Pharma; National Institute for Health and Care Research; Boston Scientific Corporation; Sanofi; AstraZeneca; Eli Lilly and Company; ResMed Foundation; Boehringer Ingelheim; Amgen; Bayer; Gedeon Richter","keywords":"Atrial fibrillation; Digoxin; Medicine; Cardiology; Internal medicine; Term (time); Beta blocker; Heart failure; Physics","score_opus":0.06499551669417274,"score_gpt":0.35396148126338745,"score_spread":0.2889659645692147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205764067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684432,0.02439576,0.0009021961,0.002861908,0.0017973818,0.00045554579,0.000015759084,0.0000661115,0.0010621011],"genre_scores_gemma":[0.9607401,0.010479266,0.0033829317,0.001042759,0.01914025,8.8288647e-7,0.00015102144,0.00019605023,0.004866721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995492,0.0010707806,0.001345023,0.0005442639,0.0011536736,0.0003942732],"domain_scores_gemma":[0.99802333,0.00013325538,0.00039880615,0.00089344464,0.00027841955,0.00027273005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018952759,0.0003665304,0.0013529942,0.00025202107,0.00014249503,0.00011657675,0.00017422957,0.00008786106,0.0009621518],"category_scores_gemma":[0.00014643486,0.00032662766,0.0035693902,0.00044271548,0.000076227865,0.00024617906,0.00009921866,0.00046634118,0.000056576424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053282693,0.000017404795,0.964134,0.000042751686,0.0053099385,0.008041286,0.00017248724,0.002933514,0.0053209714,0.000004282615,0.0020029154,0.011487633],"study_design_scores_gemma":[0.008746411,0.000053503845,0.76967776,0.000115140516,0.00082545885,0.001952487,0.000022407688,0.00008522044,0.00488586,0.000010897567,0.21333347,0.0002913762],"about_ca_topic_score_codex":0.000032799882,"about_ca_topic_score_gemma":0.0000025353258,"teacher_disagreement_score":0.21133056,"about_ca_system_score_codex":0.000111373774,"about_ca_system_score_gemma":0.0001767035,"threshold_uncertainty_score":0.9999511},"labels":[],"label_agreement":null},{"id":"W3217625748","doi":"10.1093/ehjcvp/pvab080","title":"The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis","year":2021,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Percutaneous coronary intervention; Internal medicine; Odds ratio; Conventional PCI; Confidence interval; Myocardial infarction; Cardiology; Stent; Stroke (engine)","score_opus":0.09026410061716333,"score_gpt":0.3530020672107679,"score_spread":0.26273796659360454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217625748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028642805,0.9687953,0.00014435689,0.000046364352,0.00045721402,0.0016970242,0.000062223975,0.000051597643,0.00010311105],"genre_scores_gemma":[0.02589466,0.97265625,0.0001333669,0.00017072381,0.00034714612,0.000046190093,0.00014741135,0.00028341217,0.00032082593],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.98611504,0.007585416,0.0020873807,0.00086952787,0.002609224,0.00073342817],"domain_scores_gemma":[0.9959269,0.00050076714,0.0015100823,0.001246303,0.00053130975,0.0002846371],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0067245294,0.0010296823,0.008798189,0.00069234037,0.00043598385,0.0002605279,0.0004879668,0.00022540189,0.00030279733],"category_scores_gemma":[0.00012154739,0.0006067278,0.048664603,0.00150622,0.000098454475,0.0002571416,0.00009210708,0.0015763859,0.000017645163],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034542455,0.00039936256,0.008120564,0.00041486602,0.6671853,0.003878451,0.00013019305,0.00021982993,0.0000035713058,5.514774e-7,0.000109023924,0.3191929],"study_design_scores_gemma":[0.0067078453,0.00044007343,0.003925194,0.0017889525,0.3871422,0.003874856,0.00006343608,0.0000038943176,0.00001197645,8.565265e-7,0.5953927,0.00064797176],"about_ca_topic_score_codex":0.000014166264,"about_ca_topic_score_gemma":0.0000030527765,"teacher_disagreement_score":0.5952837,"about_ca_system_score_codex":0.0003872287,"about_ca_system_score_gemma":0.00032108117,"threshold_uncertainty_score":0.99963844},"labels":[],"label_agreement":null},{"id":"W4200035084","doi":"10.1093/ehjcvp/pvab085","title":"Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Novo Nordisk Fonden; Aalborg Universitetshospital; Det Sundhedsvidenskabelige Fakultet, Københavns Universitet; Odense Universitetshospital; Gentofte Hospital; Faculty of Health and Medical Sciences, University of Western Australia; Aalborg Universitet","keywords":"Sprint; Blood pressure; Medicine; Cardiology; Heart failure; Internal medicine; Physical therapy","score_opus":0.02206226349283349,"score_gpt":0.2571214338226487,"score_spread":0.2350591703298152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200035084","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2965945,0.6950335,0.00013935135,0.0032805982,0.0015800719,0.0024869044,0.0000323594,0.0000800935,0.0007726381],"genre_scores_gemma":[0.9916774,0.0013427661,0.00019371371,0.004854525,0.0010401502,0.000025908208,0.000006723464,0.00009352807,0.0007652943],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99475396,0.002539135,0.00080709846,0.00046832167,0.0010355753,0.00039593686],"domain_scores_gemma":[0.99704075,0.00012490975,0.00027014245,0.00072924705,0.0016414645,0.0001934639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018387615,0.000358975,0.001448604,0.00018296899,0.00012928066,0.00004422489,0.00020624677,0.00007610851,0.00022932568],"category_scores_gemma":[0.00015112288,0.00023703963,0.0016661575,0.0002434295,0.00017002076,0.00015973103,0.00007465365,0.001040688,0.000012063306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078528754,0.010274615,0.08404053,0.0018192792,0.3926872,0.0047350978,0.0062389835,0.0015313817,0.04685695,0.000036649435,0.3653859,0.00786464],"study_design_scores_gemma":[0.1485492,0.0012181858,0.0300313,0.00057031866,0.0322034,0.0016735478,0.00017073682,0.000019586569,0.001863141,0.0000017315128,0.783437,0.00026181582],"about_ca_topic_score_codex":0.000039063423,"about_ca_topic_score_gemma":0.000003629391,"teacher_disagreement_score":0.6950829,"about_ca_system_score_codex":0.000019710213,"about_ca_system_score_gemma":0.00025064213,"threshold_uncertainty_score":0.96661955},"labels":[],"label_agreement":null},{"id":"W4200048331","doi":"10.1093/ehjcvp/pvab089","title":"Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Edoxaban; Medicine; Warfarin; Atrial fibrillation; Hazard ratio; Internal medicine; Stroke (engine); TIMI; Cardiology; Dosing; Confidence interval; Anesthesia; Myocardial infarction; Dabigatran; Percutaneous coronary intervention","score_opus":0.03499084357882923,"score_gpt":0.29752129149816,"score_spread":0.2625304479193308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200048331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93147355,0.06686962,0.00041233524,0.0005535612,0.00014132184,0.00045904543,0.00000816807,0.000021882817,0.00006050546],"genre_scores_gemma":[0.9437572,0.05332904,0.0011424928,0.00011550477,0.0015550973,3.5790535e-7,0.000010367419,0.000052011997,0.00003792769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772316,0.0008793691,0.00043195294,0.00041926678,0.00035165803,0.00019457388],"domain_scores_gemma":[0.99912244,0.00013998311,0.00014253521,0.00018602436,0.00007374591,0.00033528294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008459399,0.0002629029,0.0006957834,0.0001655662,0.00024662726,0.00013807867,0.000029487084,0.000038882576,0.000025626437],"category_scores_gemma":[0.00006715729,0.00021295229,0.00022640347,0.00014415213,0.00014286632,0.00031500493,0.00007311442,0.00034172952,6.236084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00981099,0.00001381164,0.9066468,0.00016899919,0.0039330316,0.0005140392,0.003180618,0.0008731454,0.024259295,0.000014254451,0.00004945527,0.05053556],"study_design_scores_gemma":[0.0312552,0.00027917302,0.9366195,0.000368862,0.0016344642,0.0010196272,0.0002646107,0.0023189024,0.00031689426,0.000030182102,0.02555105,0.0003414956],"about_ca_topic_score_codex":0.000023868613,"about_ca_topic_score_gemma":0.000003933711,"teacher_disagreement_score":0.050194062,"about_ca_system_score_codex":0.00002458328,"about_ca_system_score_gemma":0.000042152868,"threshold_uncertainty_score":0.8683942},"labels":[],"label_agreement":null},{"id":"W4200528107","doi":"10.1093/ehjcvp/pvab090","title":"Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a<i>post hoc</i>analysis of the ATHENA trial","year":2021,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"National Institute for Health and Care Research; Sanofi","keywords":"Atrial fibrillation; Post-hoc analysis; Atrial flutter; Dronedarone; Medicine; Cardiology; Internal medicine; Placebo; Flutter; Post hoc; Renal function; Amiodarone","score_opus":0.04064257678405161,"score_gpt":0.3171108632511666,"score_spread":0.276468286467115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200528107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930879,0.003147002,0.00060159416,0.0006425228,0.0011545455,0.0011892086,0.000033783454,0.000020074749,0.00012336623],"genre_scores_gemma":[0.9911271,0.0008757998,0.00028763348,0.0003302848,0.0067282566,7.1219813e-7,0.000042604748,0.0000779935,0.00052965275],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9951866,0.0017157305,0.0010480944,0.00035208272,0.0013792617,0.00031819072],"domain_scores_gemma":[0.99817765,0.00017693712,0.00046305673,0.0005591401,0.00049775164,0.0001254383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00244743,0.000273636,0.00123938,0.00029748643,0.0001754769,0.00005981828,0.0001448244,0.00006397224,0.00061469886],"category_scores_gemma":[0.00013820059,0.00017112287,0.004476309,0.0015373266,0.00009511192,0.00020947607,0.000072178846,0.00032464438,0.00000878892],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5085714,0.000053758038,0.39263958,0.00007085303,0.041573193,0.000094692055,0.0010030648,0.036469836,0.001509484,0.0000034117793,0.0005316926,0.017479056],"study_design_scores_gemma":[0.30228028,0.0021572947,0.5435545,0.0001638288,0.014025255,0.000055975404,0.00010007898,0.00024088027,0.00069439394,0.000002427909,0.13637932,0.00034575156],"about_ca_topic_score_codex":0.000012111838,"about_ca_topic_score_gemma":0.0000097916945,"teacher_disagreement_score":0.20629108,"about_ca_system_score_codex":0.000096135824,"about_ca_system_score_gemma":0.00018662591,"threshold_uncertainty_score":0.69781876},"labels":[],"label_agreement":null},{"id":"W4205656284","doi":"10.1093/ehjcvp/pvab067","title":"More knowledge about atrial fibrillation, still we need to learn","year":2021,"lang":"en","type":"editorial","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Atrial fibrillation; Flecainide; Internal medicine; Stroke (engine); Warfarin; Urinary system; Dronedarone; Cancer; Rivaroxaban; Cardiology; Dabigatran; Sinus rhythm; Intensive care medicine; Amiodarone","score_opus":0.06202149845162192,"score_gpt":0.3784305598386815,"score_spread":0.3164090613870596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205656284","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011784907,0.21516798,0.0013663052,0.0052854447,0.7715252,0.0017010043,0.00007278996,0.0003195749,0.0033832174],"genre_scores_gemma":[0.00036333044,0.057849236,0.00103864,0.00048433815,0.92195255,0.0000015157756,0.0002487095,0.00047755335,0.017584108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991814,0.0021981038,0.0014258036,0.0010200851,0.002706633,0.0008353402],"domain_scores_gemma":[0.9955711,0.0005261345,0.0003905093,0.0011019385,0.0014416731,0.00096864556],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0038927246,0.0009283655,0.002328654,0.00081097905,0.00043077706,0.0005507024,0.000423478,0.00039263765,0.0011380545],"category_scores_gemma":[0.00093382486,0.0008496853,0.00806966,0.00095453666,0.00008172489,0.00025769608,0.00022491893,0.0019497058,0.0011949847],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082131854,0.000009914415,0.00034722325,0.00022320378,0.010298303,0.0007132419,0.00077484094,0.0039385105,0.0009617398,0.0000020007544,0.9310274,0.050882306],"study_design_scores_gemma":[0.008431475,0.00025479184,0.00069710513,0.00069894514,0.00299967,0.00026911029,0.00010025453,0.000058073325,0.00016786787,0.0000034566146,0.9855008,0.0008184413],"about_ca_topic_score_codex":0.00001189095,"about_ca_topic_score_gemma":7.85242e-7,"teacher_disagreement_score":0.15731874,"about_ca_system_score_codex":0.00040575772,"about_ca_system_score_gemma":0.00077794667,"threshold_uncertainty_score":0.99977505},"labels":[],"label_agreement":null},{"id":"W4220733144","doi":"10.1093/ehjcvp/pvac017","title":"Photoinduced skin reactions of cardiovascular drugs—a systematic review","year":2022,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.; Vifor Pharma; Deutsche Herzstiftung; Deutsche Forschungsgemeinschaft; ReCor Medical; AstraZeneca; Bayer; Boehringer Ingelheim; Amgen; Medtronic; Bristol-Myers Squibb Canada; Abbott Fund","keywords":"Medicine; Adverse effect; Skin cancer; Thiazide; Cochrane Library; Basal cell carcinoma; Pharmacology; Dermatology; Cancer; Internal medicine; Meta-analysis; Basal cell; Diuretic","score_opus":0.08706301701960012,"score_gpt":0.3644292201655837,"score_spread":0.2773662031459836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220733144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000039266706,0.9856706,0.000098939214,0.000060029255,0.001293098,0.00730183,0.000038736973,0.000117085874,0.0054156994],"genre_scores_gemma":[0.000008898373,0.99588674,0.0001776182,0.0011383248,0.00127991,0.00046455953,0.00007384737,0.00052519125,0.0004449232],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98364264,0.008590043,0.003219688,0.00094449695,0.0028688952,0.00073423726],"domain_scores_gemma":[0.9947127,0.0002473311,0.0012942307,0.00290425,0.00028254846,0.00055894116],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013236212,0.0010916005,0.013602518,0.0008156888,0.00047276155,0.00009643557,0.0008412845,0.00012608232,0.002078305],"category_scores_gemma":[0.00021187405,0.00086516514,0.029681807,0.0012072868,0.000091592745,0.00016512487,0.00022592126,0.0021502164,0.0003074022],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000081980415,0.00040633153,8.201394e-8,0.70809036,0.090773426,0.0009679564,0.000115028335,0.00004796275,0.0000044437575,0.0000042432725,0.011960306,0.18762167],"study_design_scores_gemma":[0.0009374476,0.00013999316,9.308147e-7,0.25794157,0.07962911,0.00533278,0.000039461684,9.2968e-7,0.000008960904,7.15396e-7,0.6555084,0.00045968074],"about_ca_topic_score_codex":0.00004149072,"about_ca_topic_score_gemma":6.3343386e-8,"teacher_disagreement_score":0.64354813,"about_ca_system_score_codex":0.00060921,"about_ca_system_score_gemma":0.00047881505,"threshold_uncertainty_score":0.99937993},"labels":[],"label_agreement":null},{"id":"W4221116726","doi":"10.1093/ehjcvp/pvac016","title":"Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; Genome Prairie","funders":"","keywords":"Medicine; Ticagrelor; Internal medicine; Aspirin; Kidney disease; Hazard ratio; Percutaneous coronary intervention; Conventional PCI; Myocardial infarction; Stroke (engine); Clinical endpoint; Coronary artery disease; Cardiology; Diabetes mellitus; Randomized controlled trial; Confidence interval; Endocrinology","score_opus":0.008917903158099448,"score_gpt":0.23306240266298348,"score_spread":0.22414449950488402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221116726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79986864,0.19780524,0.00015547605,0.000523581,0.00031947633,0.0009792522,0.00007372417,0.00007761794,0.00019701183],"genre_scores_gemma":[0.97786736,0.015771322,0.00013289729,0.0049739303,0.00077859877,0.00008765118,0.00004669076,0.0002310884,0.00011046668],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99456173,0.0019352346,0.0005838377,0.0007082971,0.0014461726,0.000764743],"domain_scores_gemma":[0.99786645,0.000051571995,0.00012159984,0.00074388454,0.00014075404,0.0010757529],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016980853,0.0005325219,0.0010422459,0.00033468317,0.00044325538,0.00012436016,0.00024416656,0.00003899013,0.0013955102],"category_scores_gemma":[0.000019561503,0.00043203804,0.0016174633,0.00043962448,0.00019870019,0.000268886,0.0000877923,0.00092848745,0.00003251481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014124767,0.0014819251,0.8185518,0.00028030205,0.018674262,0.0054123797,0.0008966052,0.0020826424,0.0011645895,0.0000073103183,0.003910868,0.13341258],"study_design_scores_gemma":[0.030535763,0.0010574824,0.39120898,0.00018816338,0.0010902178,0.0004208073,0.00005225403,0.00011732892,0.00040017706,0.000013116545,0.5742649,0.000650799],"about_ca_topic_score_codex":0.0000031135844,"about_ca_topic_score_gemma":1.3643168e-7,"teacher_disagreement_score":0.57035404,"about_ca_system_score_codex":0.00033544024,"about_ca_system_score_gemma":0.00032491374,"threshold_uncertainty_score":0.99981314},"labels":[],"label_agreement":null},{"id":"W4225127890","doi":"10.1093/ehjcvp/pvac032","title":"Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute; University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Ticagrelor; Medicine; Percutaneous coronary intervention; Conventional PCI; Population; Coronary artery disease; Cost effectiveness; Aspirin; Myocardial infarction; Quality-adjusted life year; Stroke (engine); Internal medicine; Environmental health","score_opus":0.03805421151302679,"score_gpt":0.2911033223325112,"score_spread":0.2530491108194844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225127890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98026216,0.017451752,0.000013847615,0.000024979758,0.00033485843,0.0016640314,0.000030066612,0.0000110392075,0.0002072781],"genre_scores_gemma":[0.99880654,0.0007702711,0.000012484443,0.00011927691,0.00017704746,0.00002058856,0.000017246795,0.00006945372,0.0000070841484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909992,0.0071278336,0.00038630495,0.00027172096,0.001008762,0.00020615035],"domain_scores_gemma":[0.9989663,0.000084829546,0.000156027,0.0004599689,0.00018465192,0.00014826034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006591395,0.00019500166,0.0005623922,0.00012103366,0.00016241896,0.000017250577,0.00017263308,0.000012796073,0.00019149062],"category_scores_gemma":[0.000036986123,0.00013830807,0.00088165357,0.00020009231,0.00013671406,0.00009755873,0.0000737102,0.0003231861,0.000003090815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11940766,0.001785573,0.68313205,0.0003343127,0.018640326,0.00025039804,0.000766723,0.031681966,0.0050557517,0.0000053340063,0.00034677357,0.13859314],"study_design_scores_gemma":[0.08666616,0.0008094839,0.90462506,0.00018933798,0.0017233108,0.00011418823,0.000045081113,0.00015782125,0.00070579536,0.000010051326,0.004778704,0.00017501891],"about_ca_topic_score_codex":0.0000014396737,"about_ca_topic_score_gemma":6.2249725e-8,"teacher_disagreement_score":0.221493,"about_ca_system_score_codex":0.00013755138,"about_ca_system_score_gemma":0.00022201543,"threshold_uncertainty_score":0.5640039},"labels":[],"label_agreement":null},{"id":"W4225678126","doi":"10.1093/ehjcvp/pvac023","title":"Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; McMaster University; Population Health Research Institute; Hamilton Health Sciences; Hamilton General Hospital","funders":"Janssen Pharmaceuticals; Idorsia Pharmaceuticals; KU Leuven; Sanofi; Bayer HealthCare; Bristol-Myers Squibb; CSL Behring; Merck; Bayer; Servier; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Rivaroxaban; Aspirin; Coronary artery disease; Internal medicine; Myocardial infarction; Stroke (engine); Randomized controlled trial; Hazard ratio; Confidence interval; Warfarin; Surgery; Cardiology; Atrial fibrillation","score_opus":0.06342639653316291,"score_gpt":0.33168791625287236,"score_spread":0.26826151971970946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225678126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935118,0.0021024623,0.000020187865,0.0017167634,0.0001834033,0.0024222618,0.000008320047,0.00000788095,0.00002694045],"genre_scores_gemma":[0.9988477,0.00031432457,0.000016160771,0.0002192779,0.0001771202,0.000012957914,0.0000071425984,0.000038532697,0.0003667867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972762,0.0013081355,0.00034435283,0.00019136918,0.0007185236,0.00016140463],"domain_scores_gemma":[0.9991565,0.00007025053,0.00022358866,0.0004128239,0.000072106945,0.00006475601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009197541,0.0001806793,0.0004655162,0.000069830465,0.00041776552,0.000050036168,0.00023849704,0.00000828616,0.00009414608],"category_scores_gemma":[0.0000059642293,0.000072715724,0.00030468678,0.00022062007,0.00011531322,0.00012928675,0.00014422357,0.00021242829,4.1500385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035743073,0.00022940736,0.9527876,0.00003818563,0.0019636496,0.00008661043,0.00034321664,0.0015611473,0.00030280717,0.0000033468943,0.000048334517,0.0068926206],"study_design_scores_gemma":[0.10297129,0.0018670639,0.890658,0.00006797384,0.00044412122,0.00007267705,0.000050555547,0.00005517672,0.00005523868,8.639665e-7,0.0036670624,0.00008997982],"about_ca_topic_score_codex":0.000011597756,"about_ca_topic_score_gemma":0.0000048096335,"teacher_disagreement_score":0.06722822,"about_ca_system_score_codex":0.00018064414,"about_ca_system_score_gemma":0.000094284645,"threshold_uncertainty_score":0.32131568},"labels":[],"label_agreement":null},{"id":"W4226173040","doi":"10.1093/ehjcvp/pvac024","title":"Perioperative management of P2Y12 inhibitors in patients undergoing cardiac surgery within 1 year of PCI","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Data Storage Institute; Boston Scientific Corporation; CSL Behring; Chiesi Farmaceutici; Abbott Laboratories; Beth Israel Deaconess Medical Center; Novartis Pharmaceuticals Corporation; Bayer; AstraZeneca; Bristol-Myers Squibb Canada; Medtronic","keywords":"Medicine; Conventional PCI; Clopidogrel; Percutaneous coronary intervention; Perioperative; Myocardial infarction; Prasugrel; Cardiology; Ticagrelor; Internal medicine; Cardiac surgery; Odds ratio; Stent; Ejection fraction; Coronary artery disease; Surgery; Heart failure","score_opus":0.022972286795536728,"score_gpt":0.2649770647735248,"score_spread":0.24200477797798806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226173040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726794,0.02420267,0.00008483519,0.000044106597,0.0007973211,0.0006578157,0.00003240802,0.000026789769,0.0014746885],"genre_scores_gemma":[0.9917049,0.0072607216,0.00030010255,0.00021973165,0.0002696624,0.000015417721,0.000022870676,0.00010646695,0.000100140365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945455,0.002437997,0.0008770445,0.0003538747,0.0014417804,0.0003437748],"domain_scores_gemma":[0.9988447,0.0000687364,0.00023682318,0.00048628935,0.0001734959,0.00018996237],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003924799,0.0002784348,0.0011756439,0.0004038682,0.0002068206,0.000021848798,0.00017900397,0.000028292723,0.00033886076],"category_scores_gemma":[0.000017954708,0.00026592286,0.003371609,0.00059778075,0.000101891754,0.00015034531,0.00010359065,0.0005361007,0.00000965697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006621387,0.002721419,0.7732803,0.0012275226,0.05786363,0.0029874365,0.005142272,0.026547443,0.008792753,0.00008559703,0.008120552,0.106609665],"study_design_scores_gemma":[0.041122682,0.0022123123,0.6000179,0.0017510392,0.0046162535,0.0010694726,0.009466675,0.00006469747,0.02763704,0.000026911548,0.31037307,0.0016419482],"about_ca_topic_score_codex":0.000009433361,"about_ca_topic_score_gemma":9.5244715e-8,"teacher_disagreement_score":0.3022525,"about_ca_system_score_codex":0.00016424076,"about_ca_system_score_gemma":0.0001660782,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W4229001516","doi":"10.1093/ehjcvp/pvac012","title":"Comment on Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization","year":2022,"lang":"en","type":"letter","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bayer; Amgen; Boehringer Ingelheim; AstraZeneca; Abbott Fund","keywords":"Medicine; Guideline; Angina; Intensive care medicine; Revascularization; Dipyridamole; Drug; Canadian Cardiovascular Society; Disease; Adverse effect; Internal medicine; Cardiology; Pharmacology; Myocardial infarction","score_opus":0.059471332005563905,"score_gpt":0.35477654778109086,"score_spread":0.29530521577552693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229001516","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038673836,0.006282769,0.0066488297,0.97740966,0.0016362797,0.0024309708,0.00034943808,0.00019263197,0.0011820629],"genre_scores_gemma":[0.0060512526,0.0060311975,0.0034741026,0.9777207,0.004812754,0.00013392029,0.0008747657,0.00041643257,0.00048491784],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98186177,0.006972517,0.0016236844,0.0006327578,0.008319999,0.00058924995],"domain_scores_gemma":[0.9957317,0.0005557814,0.00086925057,0.0010195547,0.0015068331,0.00031684956],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0075033447,0.00059762865,0.0018238951,0.0007803647,0.00023440122,0.000062837986,0.000495706,0.00038087004,0.007117771],"category_scores_gemma":[0.0004634634,0.00046329878,0.0033536358,0.00070478313,0.00017427318,0.00013608494,0.00007468886,0.0050786682,0.00002980301],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003857687,0.0003954889,0.009770989,0.00014219964,0.017824037,0.0015641196,0.000080877835,0.0033845657,0.00034921418,4.320792e-7,0.9589847,0.0036456878],"study_design_scores_gemma":[0.01137164,0.0015062705,0.003993894,0.0003659721,0.00075631344,0.00041622762,0.000011826247,0.0010143325,0.00091958157,0.0000027786214,0.97925067,0.00039051255],"about_ca_topic_score_codex":0.00008755899,"about_ca_topic_score_gemma":5.085186e-7,"teacher_disagreement_score":0.020265952,"about_ca_system_score_codex":0.0006467828,"about_ca_system_score_gemma":0.0009910353,"threshold_uncertainty_score":0.99978185},"labels":[],"label_agreement":null},{"id":"W4229635210","doi":"10.1093/ehjcvp/pvab021","title":"Response: Letter to the editor","year":2021,"lang":"en","type":"letter","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Pfizer","keywords":"Computer science","score_opus":0.08358006571532085,"score_gpt":0.34944239756622786,"score_spread":0.265862331850907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229635210","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050709106,0.016021946,0.0011048869,0.9619233,0.018113008,0.0009252957,0.000014237657,0.000110311994,0.0012798951],"genre_scores_gemma":[0.00008507732,0.0013064423,0.00039143916,0.6194399,0.36125782,0.000003036754,0.000030032392,0.00020778278,0.01727849],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99076706,0.0053144107,0.0007091673,0.0005922593,0.001965106,0.0006520019],"domain_scores_gemma":[0.9976672,0.00031488203,0.00017208431,0.0012242068,0.0003430017,0.00027862212],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0057094167,0.00055057235,0.001091864,0.00037162536,0.00044614862,0.00043311276,0.0004571808,0.00020537613,0.0014453492],"category_scores_gemma":[0.00020022766,0.0003726565,0.0045715203,0.00047045614,0.00005979779,0.00011907165,0.00013509953,0.003327705,0.0017171607],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047105196,0.0000045087186,0.000111051,0.000043096865,0.00507412,0.006013757,0.00015447426,0.00017238961,0.0019841471,1.695733e-7,0.9804117,0.0055595054],"study_design_scores_gemma":[0.0021522276,0.0001285238,0.0012237375,0.00017092867,0.0010977037,0.0018030928,0.000015049035,0.0000044029443,0.0004102872,0.0000010342073,0.99257535,0.00041763688],"about_ca_topic_score_codex":0.0000026130442,"about_ca_topic_score_gemma":7.062772e-8,"teacher_disagreement_score":0.3431448,"about_ca_system_score_codex":0.00017598142,"about_ca_system_score_gemma":0.00016623823,"threshold_uncertainty_score":0.99987257},"labels":[],"label_agreement":null},{"id":"W4281251548","doi":"10.1093/ehjcvp/pvac028","title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; University of Alberta","funders":"","keywords":"Medicine; Mace; Rivaroxaban; Aspirin; Internal medicine; Randomized controlled trial; Coronary artery disease; Adverse effect; Clinical trial; Incidence (geometry); Population; Surgery; Warfarin; Conventional PCI; Myocardial infarction","score_opus":0.04912476325015902,"score_gpt":0.36706721977151824,"score_spread":0.3179424565213592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281251548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98135084,0.006736983,0.00075370265,0.004778383,0.00066697685,0.00547959,0.00006661663,0.00003696713,0.00012995714],"genre_scores_gemma":[0.97686684,0.003890075,0.00031324613,0.01733213,0.0010437946,0.00033043028,0.00007632648,0.00010507211,0.000042113523],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98129034,0.015169424,0.0013641367,0.00046435438,0.0012724601,0.0004393107],"domain_scores_gemma":[0.9967691,0.0017133605,0.00035632832,0.0006114175,0.00033095744,0.00021884995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025049746,0.0003509472,0.0015570401,0.00020563927,0.00060162577,0.00015845448,0.00022292126,0.000056149518,0.00004166893],"category_scores_gemma":[0.0018905774,0.0002199704,0.0023464966,0.00045701026,0.0001498312,0.00017201598,0.00010475925,0.0013455775,0.000004407445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88385713,0.003363163,0.016402645,0.00008621941,0.0106264325,0.0033667856,0.0058604074,0.0006933794,0.0004767015,0.000023433433,0.008290289,0.066953406],"study_design_scores_gemma":[0.5581213,0.0007611516,0.05472023,0.000067377,0.00096234906,0.0013581102,0.00081698655,0.00013251569,0.000070909955,0.000016060596,0.38268715,0.0002858743],"about_ca_topic_score_codex":0.00001274445,"about_ca_topic_score_gemma":0.0000010196665,"teacher_disagreement_score":0.37439686,"about_ca_system_score_codex":0.00011613472,"about_ca_system_score_gemma":0.00018361793,"threshold_uncertainty_score":0.89701325},"labels":[],"label_agreement":null},{"id":"W4281920016","doi":"10.1093/ehjcvp/pvac036","title":"Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Blood transfusion and management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"Janssen Pharmaceuticals; Daiichi Sankyo Company; Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; LEO Pharma; Cytori Therapeutics; Medicines Company; AstraZeneca Pharma Poland; Portola Pharmaceuticals; Boehringer Ingelheim; Pfizer; Heart and Stroke Foundation of Canada; Bayer; Servier; Rutgers, The State University of New Jersey; Bristol-Myers Squibb","keywords":"Antithrombotic; Rivaroxaban; Apixaban; Ticagrelor; Whole blood; Medicine; Drug; Pharmacology; Surgery; Warfarin; Internal medicine; Atrial fibrillation; Aspirin; Clopidogrel","score_opus":0.034815868117785156,"score_gpt":0.2796635955175815,"score_spread":0.24484772739979638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281920016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657118,0.027938755,0.002425112,0.0014335548,0.00080367015,0.0006761522,0.00002804897,0.00014237358,0.0008405353],"genre_scores_gemma":[0.9866962,0.0024741618,0.0026680236,0.005524414,0.0014889728,0.000009908718,0.00003314565,0.0002407302,0.0008644306],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957432,0.0013039852,0.00048048308,0.0005242289,0.0014696375,0.00047843697],"domain_scores_gemma":[0.99881023,0.00001830884,0.00013222998,0.000582587,0.00009655604,0.0003600881],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015657757,0.0003479544,0.0006868105,0.0002745128,0.00069973944,0.00011288744,0.00022265052,0.000021278252,0.001454828],"category_scores_gemma":[0.0000027494978,0.00029916913,0.0010655331,0.0003897458,0.00006969374,0.0001725741,0.000088320565,0.00092466053,0.00007079492],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001839114,0.0023761285,0.0048276153,0.00009713158,0.02499534,0.02978728,0.0028715346,0.011945502,0.87863207,0.000015757481,0.010035216,0.032577306],"study_design_scores_gemma":[0.048989393,0.00156497,0.015736392,0.0004253685,0.012197048,0.0724274,0.0018816771,0.0010917231,0.07138468,0.000018092562,0.7728552,0.0014280239],"about_ca_topic_score_codex":0.00017680114,"about_ca_topic_score_gemma":0.0000017555363,"teacher_disagreement_score":0.8072474,"about_ca_system_score_codex":0.00012113249,"about_ca_system_score_gemma":0.00011781031,"threshold_uncertainty_score":0.99994606},"labels":[],"label_agreement":null},{"id":"W4291000476","doi":"10.1093/ehjcvp/pvac045","title":"Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"Concept Medical; Amarin Pharma; St. Jude Medical; Ferring; Daiichi Sankyo Company; Amarin Corporation; Edwards Lifesciences; CSL Behring; Bayer; Boehringer Ingelheim; Abbott Fund","keywords":"Medicine; Hazard ratio; Myocardial infarction; Clinical endpoint; Internal medicine; Placebo; Confidence interval; Eicosapentaenoic acid; Adverse effect; Stroke (engine); Cardiology; Randomized controlled trial; Polyunsaturated fatty acid; Fatty acid","score_opus":0.03859575220016077,"score_gpt":0.33628210740597336,"score_spread":0.2976863552058126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291000476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94167155,0.045005098,0.0007630478,0.0042665866,0.005786219,0.0015265614,0.000025959003,0.000110989095,0.0008440094],"genre_scores_gemma":[0.99060637,0.0033901983,0.00022033659,0.004302159,0.0011486479,0.000044372082,0.00000977885,0.00023003558,0.000048092934],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9839899,0.009291491,0.0010389687,0.0007631998,0.0037024545,0.0012139783],"domain_scores_gemma":[0.99768907,0.00025946158,0.00023441712,0.0011405292,0.00015901774,0.0005175185],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010250597,0.0005173579,0.0015046849,0.00091459375,0.0009324577,0.00014369687,0.00084500597,0.00007080489,0.00037014112],"category_scores_gemma":[0.00016199445,0.00049609103,0.0046265763,0.00074765785,0.00013457949,0.00026081165,0.00021026767,0.0030694369,0.000034027213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068007153,0.0033701868,0.020079548,0.0012386917,0.038008824,0.019430865,0.0077165486,0.37495446,0.15111196,0.00001806019,0.04329042,0.3339797],"study_design_scores_gemma":[0.037094347,0.0041765706,0.120197184,0.0008057683,0.0015776246,0.0033888754,0.0009653062,0.0007006492,0.19160748,0.00008427418,0.6376024,0.0017995497],"about_ca_topic_score_codex":0.00014915486,"about_ca_topic_score_gemma":0.0000010957486,"teacher_disagreement_score":0.59431195,"about_ca_system_score_codex":0.0007076576,"about_ca_system_score_gemma":0.00015077948,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W4307000094","doi":"10.1093/ehjcvp/pvac058","title":"Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novo Nordisk Fonden; Novo Nordisk; AstraZeneca; Bayer; Servier; Pfizer; Bristol-Myers Squibb; Aarhus Universitetshospital; Boehringer Ingelheim","keywords":"Medicine; Antithrombotic; Atrial fibrillation; Percutaneous coronary intervention; Cardiology; Internal medicine; Myocardial infarction","score_opus":0.031172000237876432,"score_gpt":0.30163296212873386,"score_spread":0.27046096189085744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307000094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929941,0.004729633,0.00010025562,0.00026433717,0.0006418809,0.0008386839,0.000010576309,0.00004345032,0.00037707874],"genre_scores_gemma":[0.9965535,0.0007798157,0.00035969092,0.00017244482,0.0015933306,0.0000012026287,0.00004693477,0.00007598162,0.00041713627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746007,0.0008927298,0.0003978649,0.00027249454,0.0007344886,0.00024237807],"domain_scores_gemma":[0.9994496,0.000027023145,0.00010172994,0.00023937151,0.00006655619,0.00011569639],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073458295,0.00020730204,0.0004445983,0.00027159127,0.00019910748,0.000055489472,0.00006501169,0.000017341217,0.0014292985],"category_scores_gemma":[0.0000075452444,0.0001696396,0.0012844385,0.0002483345,0.000027065087,0.00016256621,0.00004209438,0.00022966438,0.000059672922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056767026,0.000050462797,0.9270502,0.00001615101,0.0027846473,0.00087524235,0.00034513825,0.017829979,0.00019240701,0.0000020326918,0.00020351494,0.044973537],"study_design_scores_gemma":[0.017126918,0.0019231546,0.7992088,0.000033286564,0.0006926266,0.0007374588,0.0000835226,0.00011687536,0.000023117806,0.0000048189613,0.17983314,0.00021628628],"about_ca_topic_score_codex":0.000009138227,"about_ca_topic_score_gemma":6.1045154e-7,"teacher_disagreement_score":0.17962962,"about_ca_system_score_codex":0.0003793289,"about_ca_system_score_gemma":0.000036640926,"threshold_uncertainty_score":0.9994835},"labels":[],"label_agreement":null},{"id":"W4317105117","doi":"10.1093/ehjcvp/pvad006","title":"Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"Janssen Pharmaceuticals; Abbott Vascular; CytoSorbents Europe; MicroPort; Idorsia Pharmaceuticals; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; PharmaMar; Eisai; Sanofi; Abiomed; Amarin Pharma; Novo Nordisk; AtriCure; Daiichi-Sankyo; Medicines Company; AstraZeneca; Amarin Corporation; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Daiichi Sankyo Europe; Gilead Sciences; Amgen; Pfizer; Boston Scientific Corporation; National Science Foundation","keywords":"Ticagrelor; Medicine; Aspirin; Percutaneous coronary intervention; Internal medicine; Hazard ratio; Conventional PCI; Myocardial infarction; Clinical endpoint; Placebo; Stroke (engine); Cardiology; Randomized controlled trial; Confidence interval","score_opus":0.019628977588347165,"score_gpt":0.2786518573281694,"score_spread":0.25902287973982224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317105117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946839,0.0030290566,0.00056256197,0.00008490394,0.0002742076,0.0011545289,0.00002803369,0.00008277449,0.00009999028],"genre_scores_gemma":[0.99556625,0.0032562087,0.00020057063,0.0002636846,0.00034009878,0.000013003899,0.00003745198,0.00012979367,0.00019296372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945723,0.00222118,0.00072481256,0.00051418203,0.0014889752,0.00047855164],"domain_scores_gemma":[0.9982459,0.000132814,0.0002828971,0.0008314224,0.0002486491,0.0002583218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021032202,0.00039903633,0.0013673165,0.00062071224,0.000263273,0.00006908434,0.00030884298,0.00006138871,0.00026989327],"category_scores_gemma":[0.000046095978,0.0002205575,0.003127645,0.0025624048,0.00019648175,0.00017869621,0.000057960555,0.0006781038,0.00002348932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093740724,0.0008246464,0.77144605,0.0001417272,0.07967034,0.0044281404,0.0006657717,0.014199653,0.000252677,0.000002143115,0.00023876398,0.03438936],"study_design_scores_gemma":[0.12999012,0.0033021215,0.83685046,0.0007631472,0.016810317,0.0022255788,0.0003299033,0.00043689276,0.0003232219,0.0000037781901,0.008457263,0.00050721044],"about_ca_topic_score_codex":0.00004391168,"about_ca_topic_score_gemma":0.000040975934,"teacher_disagreement_score":0.0654044,"about_ca_system_score_codex":0.00013673265,"about_ca_system_score_gemma":0.00019563719,"threshold_uncertainty_score":0.8994074},"labels":[],"label_agreement":null},{"id":"W4323067192","doi":"10.1093/ehjcvp/pvad016","title":"Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Ticagrelor; Aspirin; Clopidogrel; Internal medicine; Hazard ratio; Acute coronary syndrome; Myocardial infarction; Coronary artery disease; Stroke (engine); Antithrombotic; Rivaroxaban; Cardiology; Confidence interval; Warfarin; Atrial fibrillation","score_opus":0.06261888568394085,"score_gpt":0.3450688773441085,"score_spread":0.28244999166016765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323067192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9541658,0.04186493,0.0005943275,0.0000750744,0.00040608965,0.0021292414,0.00046590934,0.000027013288,0.00027157034],"genre_scores_gemma":[0.98876494,0.010489175,0.00021972627,0.00003779203,0.00021689486,0.000007325686,0.00009651051,0.00012402407,0.00004361588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9749535,0.020035347,0.0022198302,0.0006190522,0.0017304107,0.00044188966],"domain_scores_gemma":[0.99521905,0.00052778784,0.0019855273,0.000920055,0.0011520212,0.00019556549],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01859616,0.00047752974,0.0030503187,0.00024304393,0.00027018314,0.000053268326,0.00028657907,0.00007687844,0.0000071715967],"category_scores_gemma":[0.0004632911,0.0003297841,0.0067420155,0.00058693433,0.00035330383,0.00018634475,0.00022883328,0.00058621605,6.573308e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022306102,0.0004949899,0.5294132,0.0010517695,0.3471928,0.0002600538,0.001983403,0.10776631,0.0023092157,0.0000142508325,0.00033272427,0.0069506406],"study_design_scores_gemma":[0.013526691,0.00067572953,0.9270122,0.00062737,0.055491045,0.00012617785,0.0007487841,0.00007059558,0.00027497206,0.000016567117,0.001139941,0.00028992546],"about_ca_topic_score_codex":0.00002741942,"about_ca_topic_score_gemma":0.0000071749305,"teacher_disagreement_score":0.39759895,"about_ca_system_score_codex":0.00019746395,"about_ca_system_score_gemma":0.00017821325,"threshold_uncertainty_score":0.9999154},"labels":[],"label_agreement":null},{"id":"W4360941970","doi":"10.1093/ehjcvp/pvad023","title":"Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Cardiovascular and Diving-Related Complications","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"Bayer","keywords":"Medicine; Patent foramen ovale; Hazard ratio; Percutaneous; Confidence interval; Cohort; Stroke (engine); Proportional hazards model; Myocardial infarction; Propensity score matching; Internal medicine; Clinical endpoint; Closure (psychology); Cardiology; Vascular closure device; Surgery; Clinical trial","score_opus":0.07864490385866553,"score_gpt":0.3430916507234557,"score_spread":0.2644467468647902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360941970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983096,0.011740526,0.0003022229,0.00022138646,0.0005381666,0.00064093573,0.000022332471,0.00017178777,0.003266657],"genre_scores_gemma":[0.9955787,0.0030401396,0.000089661655,0.00021988363,0.0006361575,0.0000050357858,0.000014717354,0.00013987525,0.00027581796],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963103,0.0010099178,0.0006123746,0.00038142526,0.0011233437,0.00056263525],"domain_scores_gemma":[0.99815995,0.00006557498,0.00013652384,0.0010662837,0.0002446324,0.0003270328],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0023208926,0.0003368779,0.00082736526,0.00025811951,0.00042809127,0.0001143075,0.00035738116,0.00007458458,0.00014813688],"category_scores_gemma":[0.000057399906,0.00022789602,0.010309081,0.001042829,0.00008136147,0.00013134786,0.00008932103,0.00083198206,0.00018356889],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010636366,0.0006701737,0.12260771,0.00018994337,0.096964404,0.011332279,0.0019180763,0.15940775,0.5011675,0.000024437699,0.03672315,0.06793095],"study_design_scores_gemma":[0.017882565,0.0010679894,0.78230584,0.0007025769,0.005557651,0.08662323,0.00028004523,0.0016714958,0.006868929,0.00011104729,0.095887296,0.0010413461],"about_ca_topic_score_codex":0.0000442123,"about_ca_topic_score_gemma":2.5534388e-7,"teacher_disagreement_score":0.6596981,"about_ca_system_score_codex":0.00014585473,"about_ca_system_score_gemma":0.00021968374,"threshold_uncertainty_score":0.99960244},"labels":[],"label_agreement":null},{"id":"W4362602865","doi":"10.1093/ehjcvp/pvad025","title":"Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health; University of Glasgow; Tenovus; Wellcome Trust; Chief Scientist Office; Cancer Research UK; UK Research and Innovation; Scottish Government; British Heart Foundation; Medical Research Council; International Seafood Sustainability Foundation; NHS Greater Glasgow and Clyde; Johns Hopkins University; Cisco Systems","keywords":"Medicine; Fasudil; Vasoconstriction; Internal medicine; Sirius Red; Histopathology; Electrical impedance myography; Endothelial dysfunction; RHOA; Rho-associated protein kinase; Gastroenterology; Endocrinology; Pathology; Vasodilation; Immunohistochemistry; Biology","score_opus":0.05154086754211451,"score_gpt":0.3601143848326227,"score_spread":0.3085735172905082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362602865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.545435,0.053570602,0.3497351,0.03186215,0.0038324327,0.011933525,0.0012667901,0.0016060146,0.00075833336],"genre_scores_gemma":[0.75237715,0.03489172,0.037833557,0.16381866,0.0069629317,0.0005142908,0.0006272231,0.0016616205,0.0013128183],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99456286,0.0011922569,0.0009811608,0.0007798635,0.0015937291,0.00089010346],"domain_scores_gemma":[0.9958944,0.0006441739,0.00031559457,0.0011788849,0.00070856296,0.0012584374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00675434,0.0006187434,0.0013876781,0.00092796277,0.000570382,0.0001262057,0.0005348638,0.00012965049,0.0009349893],"category_scores_gemma":[0.0007011259,0.00054018426,0.005080313,0.0009197446,0.00018338178,0.00033441756,0.00007703065,0.00066750246,0.00023665543],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019488471,0.0007228549,0.0006148697,0.0009802695,0.015982097,0.0015286586,0.0017330373,0.003377744,0.90696156,0.0002264331,0.06024463,0.005678984],"study_design_scores_gemma":[0.035383046,0.002002246,0.0036883007,0.00029861316,0.0010511773,0.00239974,0.00019447571,0.00067673734,0.1035608,0.0011431216,0.84880024,0.0008014935],"about_ca_topic_score_codex":0.00003489669,"about_ca_topic_score_gemma":2.5212066e-7,"teacher_disagreement_score":0.80340075,"about_ca_system_score_codex":0.000272786,"about_ca_system_score_gemma":0.000814109,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W4367549649","doi":"10.1093/ehjcvp/pvad031","title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Princess Margaret Cancer Centre; St. Michael's Hospital; Ted Rogers Centre for Heart Research; Sunnybrook Health Science Centre; University Health Network; Toronto General Hospital; University of Toronto; Mount Sinai Hospital; Health Sciences Centre","funders":"Medical Research Council; Canadian Institutes of Health Research; Canadian Cancer Society; National Health and Medical Research Council; Heart and Stroke Foundation of Canada","keywords":"Cardiotoxicity; Medicine; Cardiac dysfunction; Internal medicine; Cancer; Cardiology; Statin; Oncology; Chemotherapy; Heart failure","score_opus":0.03237390814703667,"score_gpt":0.3228593499428082,"score_spread":0.2904854417957715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367549649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993118,0.0022878463,0.00023630552,0.00038294616,0.0015128738,0.001546446,0.000114328905,0.00022205285,0.0005792121],"genre_scores_gemma":[0.980359,0.015563872,0.00022788008,0.00091542787,0.0022925367,0.000073076335,0.00005014145,0.00020022674,0.0003178403],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9940005,0.0024430268,0.0008078,0.0006893087,0.0013195175,0.00073986634],"domain_scores_gemma":[0.99810576,0.00013268176,0.00021441383,0.0005671127,0.00034857498,0.000631433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042322795,0.0004514165,0.0010749401,0.0006117113,0.00045846484,0.000104810104,0.00018027937,0.0001056465,0.00011931744],"category_scores_gemma":[0.00020444831,0.0004315337,0.0019403438,0.0012304054,0.000056912086,0.00030023174,0.00008146864,0.000910488,0.0002462023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00101814,0.0004311731,0.4127777,0.00010276358,0.004447014,0.0002386245,0.0027636236,0.006766943,0.48145902,4.4532806e-7,0.010238578,0.07975599],"study_design_scores_gemma":[0.005661902,0.00035793195,0.7566482,0.0003348153,0.00044925086,0.00008086579,0.00007334152,0.00010185375,0.16681246,0.000005742343,0.069024265,0.00044938555],"about_ca_topic_score_codex":0.00047687156,"about_ca_topic_score_gemma":0.000018809758,"teacher_disagreement_score":0.34387052,"about_ca_system_score_codex":0.00089397206,"about_ca_system_score_gemma":0.00013770572,"threshold_uncertainty_score":0.9998136},"labels":[],"label_agreement":null},{"id":"W4367552266","doi":"10.1093/ehjcvp/pvad032","title":"Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease","year":2023,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Abbott Vascular; St. Jude Medical; CytoSorbents Europe; Intas Pharmaceuticals; Idorsia Pharmaceuticals; Terumo; Sanofi; Abiomed; Eisai; Biosensors International Group; Medicure; InfraRedx; Medicines Company; Canada Excellence Research Chairs, Government of Canada; Osprey Medical; Novo Nordisk; Daiichi-Sankyo; Regeneron Pharmaceuticals; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Biotronik; AstraZeneca; CSL Behring; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bayer HealthCare; Cilag; Cardinal Health; Edwards Lifesciences; Amgen; Pfizer; Universität Basel","keywords":"Antithrombotic; Medicine; Intensive care medicine; Coronary artery disease; Terminology; Regimen; Fibrinolytic agent; Cardiology; Internal medicine","score_opus":0.07401050145086814,"score_gpt":0.3403840332688821,"score_spread":0.266373531818014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367552266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012425193,0.9833776,0.00009875074,0.000018588407,0.00051686476,0.0030395864,0.000084548185,0.00023343289,0.0002054461],"genre_scores_gemma":[0.0020090635,0.99540323,0.00010094751,0.00014951797,0.0010797426,0.00005880682,0.00025274325,0.00070689135,0.00023907582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99247086,0.0028660737,0.0011596751,0.0010310803,0.0015340532,0.0009382613],"domain_scores_gemma":[0.9971072,0.00010697806,0.0003134938,0.0013158337,0.00020594873,0.00095055945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014026962,0.0012546126,0.0044030687,0.00073455845,0.0002647445,0.00036488415,0.00039244723,0.00014290497,0.0002419938],"category_scores_gemma":[0.000024121167,0.00085518934,0.007516617,0.0009792045,0.00020076589,0.00045056772,0.00005527059,0.0010346181,0.00051877525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014011933,0.0017472561,0.007352949,0.007123766,0.050898325,0.014926766,0.00016257037,0.0010064818,0.0000018259179,0.0000042017127,0.0005459684,0.9148287],"study_design_scores_gemma":[0.013786641,0.00096868735,0.050585806,0.014278513,0.013078999,0.0009637796,0.000046033907,0.000004940281,7.6223427e-7,0.0000047547846,0.9053029,0.0009782205],"about_ca_topic_score_codex":0.000010477348,"about_ca_topic_score_gemma":7.2655547e-7,"teacher_disagreement_score":0.9138505,"about_ca_system_score_codex":0.000557875,"about_ca_system_score_gemma":0.0011726685,"threshold_uncertainty_score":0.9993899},"labels":[],"label_agreement":null},{"id":"W4376223844","doi":"10.1093/ehjcvp/pvad034","title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; National Research, Development and Innovation Office; National Institutes of Health; Semmelweis Egyetem; European Cooperation in Science and Technology; European Commission; Comunidad de Madrid","keywords":"Medicine; Heart failure; Ejection fraction; Internal medicine; Ezetimibe; Pharmacotherapy; Cardiology; Atrial fibrillation; Intensive care medicine; Heart failure with preserved ejection fraction; Pharmacology; Statin","score_opus":0.0734493826543966,"score_gpt":0.35456561136049297,"score_spread":0.28111622870609637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376223844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9380375,0.037677124,0.013049248,0.003551878,0.00077738805,0.0012599437,0.00003763492,0.0006435002,0.004965799],"genre_scores_gemma":[0.92284775,0.060883276,0.0015225349,0.008158906,0.0043734116,0.000030210389,0.00004749783,0.00030351183,0.0018328765],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948794,0.0012208067,0.0008159361,0.0007878145,0.0014317463,0.00086426875],"domain_scores_gemma":[0.9982346,0.00007272834,0.00011723866,0.00048599936,0.00015453622,0.00093486655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003930918,0.00054625946,0.0012670829,0.00091046526,0.00032384726,0.00027743916,0.00026894725,0.00009888462,0.0019729938],"category_scores_gemma":[0.000029907374,0.00047947376,0.003138613,0.0015192583,0.00012540961,0.0004618874,0.00008550236,0.0012386005,0.00035345822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009043575,0.0006102146,0.004692588,0.0001489083,0.02645438,0.012636597,0.0012033139,0.014281594,0.7124749,0.00004073002,0.10453804,0.1220144],"study_design_scores_gemma":[0.030871326,0.00031907932,0.036500208,0.0003989804,0.0018571514,0.0060473247,0.00059500395,0.0025456457,0.014679272,0.00007020031,0.9051453,0.00097051694],"about_ca_topic_score_codex":0.00004728093,"about_ca_topic_score_gemma":9.359042e-7,"teacher_disagreement_score":0.80060726,"about_ca_system_score_codex":0.00014974312,"about_ca_system_score_gemma":0.0002400143,"threshold_uncertainty_score":0.9997657},"labels":[],"label_agreement":null},{"id":"W4381046757","doi":"10.1093/ehjcvp/pvad044","title":"Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?","year":2023,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Residual risk; Medicine; Atherosclerotic cardiovascular disease; Internal medicine; Eicosapentaenoic acid; Triglyceride; Disease; Lipoprotein; Cholesterol; Epidemiology; Primary prevention; Endocrinology; Fatty acid; Biology; Biochemistry","score_opus":0.10143199576751306,"score_gpt":0.35734081393315903,"score_spread":0.255908818165646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381046757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016797207,0.9908469,0.0004345705,0.00016832165,0.0017104002,0.004671532,0.00020925474,0.0005800463,0.0012110211],"genre_scores_gemma":[0.00017242868,0.9863396,0.0004700179,0.0015655557,0.008348565,0.00027971147,0.00022923829,0.0017077264,0.00088710553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9800877,0.007926165,0.0031658818,0.0025514595,0.0040832125,0.00218556],"domain_scores_gemma":[0.9923536,0.00031112274,0.0006376239,0.0044026333,0.00044230078,0.001852713],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.012508167,0.0024225505,0.0123497965,0.0023824484,0.00057764724,0.000624934,0.0013740744,0.00053446606,0.0006310526],"category_scores_gemma":[0.00025309154,0.0020146354,0.041279063,0.0032553198,0.00030817097,0.000558918,0.0003006398,0.0045766677,0.0020175865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002488603,0.00022200131,0.00005901645,0.0121723255,0.07505356,0.013498034,0.00014539086,0.00032902736,0.0000059369886,0.0000014719227,0.0059259045,0.89233845],"study_design_scores_gemma":[0.0061293817,0.00019231495,0.0007301193,0.020623127,0.025930854,0.006174552,0.00003744088,0.000048249643,0.000017971177,0.000033597895,0.93820614,0.0018762323],"about_ca_topic_score_codex":0.0003040283,"about_ca_topic_score_gemma":0.0000011964254,"teacher_disagreement_score":0.93228024,"about_ca_system_score_codex":0.00091726944,"about_ca_system_score_gemma":0.0014067878,"threshold_uncertainty_score":0.9988512},"labels":[],"label_agreement":null},{"id":"W4386878555","doi":"10.1093/ehjcvp/pvad054","title":"Cardiovascular preventive actions","year":2023,"lang":"en","type":"editorial","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.04662562444257853,"score_gpt":0.345710432397644,"score_spread":0.2990848079550655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386878555","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045683281,0.15140393,0.0022982052,0.00032972358,0.8363756,0.0022993484,0.0002403971,0.00085412676,0.0057418556],"genre_scores_gemma":[0.00053019443,0.12743713,0.0006680806,0.0003811294,0.8641813,0.00011417639,0.00034013478,0.001340345,0.0050075487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9815748,0.005311439,0.0016974534,0.001847696,0.0077589653,0.0018096607],"domain_scores_gemma":[0.9919627,0.0004470854,0.000450395,0.0038121312,0.0016932319,0.0016344762],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.016331417,0.0014903902,0.004394326,0.0009885471,0.0011144116,0.00049361604,0.00086387637,0.00085280545,0.00040225504],"category_scores_gemma":[0.0009716375,0.001350766,0.028264917,0.0012972474,0.000231939,0.0003957389,0.0002534206,0.0068852548,0.0027111757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024632277,0.00019165326,0.000011150382,0.0005781069,0.073490664,0.005182417,0.00017235664,0.0005877664,0.00026854078,0.0000012854634,0.8562747,0.06299498],"study_design_scores_gemma":[0.007943484,0.00046040208,0.00037760352,0.0010624377,0.010949441,0.003136605,0.00007850303,0.000015355863,0.0003665023,0.000014314933,0.974398,0.0011973185],"about_ca_topic_score_codex":0.0001688966,"about_ca_topic_score_gemma":0.000002064088,"teacher_disagreement_score":0.11812328,"about_ca_system_score_codex":0.0010007774,"about_ca_system_score_gemma":0.0018345972,"threshold_uncertainty_score":0.9997845},"labels":[],"label_agreement":null},{"id":"W4389707196","doi":"10.1093/ehjcvp/pvad098","title":"The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?","year":2023,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Mechanical Circulatory Support Devices","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Cardiogenic shock; Medicine; Nothing; Harm; Library science; Cardiology; Internal medicine; Political science; Law; Myocardial infarction; Philosophy","score_opus":0.03598854394005503,"score_gpt":0.28966631385436653,"score_spread":0.2536777699143115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389707196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973656,0.021407833,0.00068941223,0.00052327936,0.0012857235,0.0007878024,0.000019187164,0.00033944455,0.0012913034],"genre_scores_gemma":[0.9950756,0.002301035,0.00033155264,0.0010311422,0.0008433104,0.000026801992,0.0000023342993,0.00024309209,0.00014513859],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626285,0.0008203666,0.00078921515,0.00037863306,0.0009661848,0.0007827583],"domain_scores_gemma":[0.9984427,0.00016902635,0.00005622798,0.0007009966,0.00009850993,0.0005325099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037335944,0.00034320602,0.00067428924,0.00037210406,0.00022771269,0.00016068171,0.0007015475,0.00005000747,0.00018814478],"category_scores_gemma":[0.000076902776,0.0002536025,0.0011266959,0.001042235,0.000024806692,0.00017329823,0.00016783882,0.00052618166,0.00095375936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003473382,0.00003348963,0.0034347908,0.00008474558,0.0048837606,0.0014771982,0.00534738,0.37988156,0.47138688,0.000013666506,0.013791279,0.119317904],"study_design_scores_gemma":[0.00086831785,0.000079722966,0.0034925926,0.00007352634,0.00009203532,0.00044874585,0.00022794856,0.0012745277,0.041835494,0.0000104783185,0.95123863,0.00035796594],"about_ca_topic_score_codex":0.00001084556,"about_ca_topic_score_gemma":0.0000044084222,"teacher_disagreement_score":0.93744737,"about_ca_system_score_codex":0.00022872759,"about_ca_system_score_gemma":0.00003971723,"threshold_uncertainty_score":0.9999916},"labels":[],"label_agreement":null},{"id":"W4389707292","doi":"10.1093/ehjcvp/pvad101","title":"Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis","year":2023,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Antithrombotic; Odds ratio; Internal medicine; Confidence interval; Relative risk","score_opus":0.1405191708163407,"score_gpt":0.417201937457392,"score_spread":0.2766827666410513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389707292","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010590239,0.9953469,0.00009731429,0.000013772265,0.00051239034,0.002611615,0.00017294931,0.00008909432,0.00009691901],"genre_scores_gemma":[0.0025526956,0.99422973,0.000089514164,0.00057165656,0.0014648718,0.0002756232,0.00026225133,0.00043377903,0.000119856464],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99181575,0.003496147,0.0015692544,0.0009328129,0.0013384459,0.0008476207],"domain_scores_gemma":[0.9977256,0.0001311277,0.00037856444,0.00100801,0.00021103969,0.0005456415],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020393129,0.0010424678,0.007857834,0.000978937,0.0001693046,0.00020367122,0.00026482728,0.00014405095,0.0008637438],"category_scores_gemma":[0.000007814683,0.0007215418,0.12908934,0.0020540778,0.000059029975,0.00016143169,0.000037204307,0.00095188257,0.000575284],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015688121,0.0003617272,0.005363574,0.0011011697,0.817489,0.00035768098,0.00006929265,0.0002292205,4.857922e-8,1.2369907e-7,0.00025435077,0.1746169],"study_design_scores_gemma":[0.0030122048,0.00020047698,0.03332378,0.00052459183,0.5897996,0.00014198245,0.000002661801,0.0000013175257,1.2733291e-7,0.000002761295,0.37252614,0.00046435255],"about_ca_topic_score_codex":0.000012225279,"about_ca_topic_score_gemma":4.7496604e-7,"teacher_disagreement_score":0.37227178,"about_ca_system_score_codex":0.00021912862,"about_ca_system_score_gemma":0.00018449932,"threshold_uncertainty_score":0.9995236},"labels":[],"label_agreement":null},{"id":"W4391211868","doi":"10.1093/ehjcvp/pvae006","title":"Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Max Kade Foundation","keywords":"Medicine; Myocardial infarction; Ischaemic heart disease; Internal medicine; Disease; Type 2 diabetes; Cardiology; Diabetes mellitus; Endocrinology","score_opus":0.013863793144129877,"score_gpt":0.2630256025279066,"score_spread":0.2491618093837767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391211868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574726,0.039203037,0.000007557103,0.0008151104,0.0005335421,0.0018713489,0.000007791598,0.00003363092,0.00005535077],"genre_scores_gemma":[0.9946138,0.003370234,0.000034144483,0.0015472713,0.00027268144,0.00004337108,0.000010525521,0.00007412888,0.000033832974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680287,0.0011068487,0.00037634635,0.00043643164,0.0009277724,0.00034973214],"domain_scores_gemma":[0.9990027,0.00019780976,0.000041662293,0.0004318732,0.00004960516,0.00027632972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016072204,0.00034515423,0.0008587788,0.00040049452,0.00008430465,0.000116084666,0.00009543927,0.000025645808,0.000008043938],"category_scores_gemma":[0.00007661811,0.00020807852,0.00094451406,0.00030430433,0.00009632813,0.00021005966,0.000040826842,0.00039149428,0.00000904711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075903954,0.00071258156,0.9575814,0.0003658928,0.012482962,0.0007568646,0.0004438202,0.00055576785,0.000113601505,0.000008738329,0.00077667844,0.018611284],"study_design_scores_gemma":[0.040298767,0.0008866608,0.9370043,0.00038779617,0.0026395777,0.0000053146455,0.000016973925,0.00004711684,0.00005009931,0.0000134794955,0.018435275,0.00021462729],"about_ca_topic_score_codex":0.000012573662,"about_ca_topic_score_gemma":1.9933867e-7,"teacher_disagreement_score":0.037141178,"about_ca_system_score_codex":0.00006356399,"about_ca_system_score_gemma":0.000051280513,"threshold_uncertainty_score":0.84851956},"labels":[],"label_agreement":null},{"id":"W4392596641","doi":"10.1093/ehjcvp/pvae017","title":"Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Bayer","keywords":"Compass; Baseline (sea); Medicine; Internal medicine; Acute coronary syndrome; Dual (grammatical number); Cardiology; Biology; Geography; Cartography; Philosophy","score_opus":0.02427486823496835,"score_gpt":0.30313378165067767,"score_spread":0.27885891341570934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392596641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553449,0.03972409,0.002807614,0.00010062534,0.00061591587,0.001150948,0.00007785939,0.0001135534,0.000064466694],"genre_scores_gemma":[0.9913923,0.006639152,0.00036560636,0.00044760393,0.0008645206,0.000015718873,0.000058131107,0.00018803851,0.000028933156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940794,0.002193939,0.0011410939,0.0007066104,0.001324231,0.0005547092],"domain_scores_gemma":[0.9982268,0.0001475721,0.00015115453,0.0006385569,0.0002951997,0.00054067554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0055593355,0.0004569968,0.0013777205,0.00049053633,0.00016844405,0.00009806495,0.00015828382,0.00007865088,0.00020258482],"category_scores_gemma":[0.00004564636,0.00036375134,0.0024995054,0.00078543206,0.00011746579,0.00030662972,0.00006138613,0.0011066695,0.00007718125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073222867,0.0021186,0.58854365,0.00036457065,0.022874821,0.01718503,0.00045406516,0.0104073435,0.0016115459,0.000008437486,0.0012062663,0.3479034],"study_design_scores_gemma":[0.019538516,0.003119603,0.9413845,0.0014846824,0.0014808439,0.0038888024,0.000106466185,0.00034172618,0.00074047555,0.000008183509,0.02739753,0.0005086926],"about_ca_topic_score_codex":0.000015410002,"about_ca_topic_score_gemma":0.000001980507,"teacher_disagreement_score":0.35284084,"about_ca_system_score_codex":0.00021227168,"about_ca_system_score_gemma":0.00025285129,"threshold_uncertainty_score":0.99988145},"labels":[],"label_agreement":null},{"id":"W4394742007","doi":"10.1093/ehjcvp/pvae013","title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"European Commission; Medical Research Council; National Institute for Health and Care Research; National Institutes of Health; Barts Charity","keywords":"Medicine; Pharmacotherapy; Polypharmacy; Intensive care medicine; Clinical trial; Heart failure; Repurposing; Guideline; Pharmacology; Drug; Internal medicine; Pathology","score_opus":0.16639384425071016,"score_gpt":0.4121024644585225,"score_spread":0.24570862020781234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394742007","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021222295,0.99253845,0.0014239097,0.0002995098,0.0016467307,0.0018038108,0.000032042077,0.00018557758,0.0018577639],"genre_scores_gemma":[0.00023358443,0.9906503,0.0009135346,0.0011888036,0.005070008,0.00003097568,0.00003813087,0.0004789308,0.0013957198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922773,0.001961535,0.0016427756,0.001327296,0.001834105,0.00095698994],"domain_scores_gemma":[0.99753267,0.00011025969,0.00023727673,0.0007077875,0.00019454266,0.0012174422],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0040752697,0.0013347666,0.0049343663,0.0011761342,0.00024501418,0.0005399154,0.0004368825,0.0003431343,0.00093732687],"category_scores_gemma":[0.00002990059,0.0009768752,0.008750494,0.0010994184,0.0001466659,0.00037606788,0.00014624406,0.0031443662,0.0006052761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015785344,0.00018408506,0.0000068767363,0.0022230202,0.026136534,0.008433457,0.00013114164,0.00017316153,0.00078932586,0.00001707094,0.025167558,0.93657994],"study_design_scores_gemma":[0.006672997,0.00017699103,0.00015943673,0.005207505,0.014726554,0.022600569,0.000037706388,0.00013181525,0.00002235132,0.000014934739,0.94938654,0.00086262356],"about_ca_topic_score_codex":0.000036634054,"about_ca_topic_score_gemma":4.943113e-7,"teacher_disagreement_score":0.9357173,"about_ca_system_score_codex":0.00041889446,"about_ca_system_score_gemma":0.0010707648,"threshold_uncertainty_score":0.999976},"labels":[],"label_agreement":null},{"id":"W4395109358","doi":"10.1093/ehjcvp/pvae025","title":"Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; Sanofi (Canada); University of Alberta; St. Michael's Hospital","funders":"Duke Clinical Research Institute; American Regent; St. Jude Medical; Esperion Therapeutics; Idorsia Pharmaceuticals; Servier; MyoKardia; Novo Nordisk; Daiichi-Sankyo; Regado Biosciences; Belvoir Media Group; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Boston VA Research Institute; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; University of Toronto; Heart and Stroke Foundation of Canada; HLS Therapeutics; GlaxoSmithKline; Amgen; Sanofi; American Heart Association","keywords":"Alirocumab; PCSK9; Medicine; Internal medicine; LDL receptor; Cholesterol; Total cholesterol","score_opus":0.05757911266128796,"score_gpt":0.325943084739561,"score_spread":0.26836397207827306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395109358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051106154,0.989333,0.00010304546,0.000066466004,0.0026887092,0.0020579672,0.0001412683,0.00005638572,0.0004425589],"genre_scores_gemma":[0.0017456833,0.9929359,0.00039661958,0.0003636975,0.0040166494,0.000020452955,0.000061697545,0.00035706806,0.00010221532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901062,0.0040047043,0.002304168,0.0007017525,0.0024428358,0.00044031546],"domain_scores_gemma":[0.9963755,0.00010618038,0.00086064904,0.0018849978,0.0004088742,0.0003637933],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0024109865,0.0007205987,0.004044986,0.00037159625,0.00018390418,0.00007192237,0.0005415866,0.00024264949,0.000102440106],"category_scores_gemma":[0.00008997823,0.00046579482,0.013975248,0.0010355047,0.00016601947,0.00016262804,0.0001886668,0.0019481058,0.0000921587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009831423,0.00012638995,0.000012366861,0.0064173127,0.018470982,0.00035259887,0.000522346,0.000029429715,0.0003163012,0.000008212195,0.002385844,0.9712599],"study_design_scores_gemma":[0.0020146822,0.00018242095,0.00036336484,0.020793516,0.011197223,0.0012245738,0.000037626727,0.000004503357,0.00044417553,0.00001566123,0.963338,0.00038423683],"about_ca_topic_score_codex":0.00010737139,"about_ca_topic_score_gemma":9.464284e-7,"teacher_disagreement_score":0.9708757,"about_ca_system_score_codex":0.00031996248,"about_ca_system_score_gemma":0.0008438577,"threshold_uncertainty_score":0.9997794},"labels":[],"label_agreement":null},{"id":"W4399250824","doi":"10.1093/ehjcvp/pvae043","title":"Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Affect (linguistics); Statin; Medicine; Primary prevention; Register (sociolinguistics); Internal medicine; Psychology; Disease","score_opus":0.053366149448841396,"score_gpt":0.3819393901106707,"score_spread":0.3285732406618293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399250824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6453207,0.027714906,0.31675997,0.0007169222,0.001503195,0.007146767,0.000037955844,0.00024448783,0.0005550712],"genre_scores_gemma":[0.94837695,0.0009576311,0.041562237,0.0014598725,0.004601039,0.0004230127,0.000036287158,0.00053515664,0.0020478093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99205667,0.0045198533,0.000856179,0.0007609851,0.0012287786,0.00057753426],"domain_scores_gemma":[0.9983656,0.00022745742,0.00012818618,0.0007555771,0.00021765126,0.0003055181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015042021,0.00041523285,0.0010115067,0.00053223793,0.00025590355,0.0003123456,0.00020568416,0.00006785268,0.00010043666],"category_scores_gemma":[0.00009222515,0.00028150354,0.002957387,0.00047543953,0.00003189304,0.00027029874,0.00003618701,0.0007949869,0.000041644453],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013212922,0.0010975078,0.008174165,0.0021488955,0.0073655555,0.0035202506,0.0042801453,0.001684396,0.014542874,0.0000032686867,0.0007943416,0.95506734],"study_design_scores_gemma":[0.08274584,0.009103686,0.13135946,0.008116953,0.010981378,0.0070983213,0.004726724,0.013605278,0.014018682,0.0002756956,0.7147772,0.0031908127],"about_ca_topic_score_codex":0.000045539986,"about_ca_topic_score_gemma":0.000009958632,"teacher_disagreement_score":0.9518765,"about_ca_system_score_codex":0.00038702754,"about_ca_system_score_gemma":0.0004219843,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W4399454668","doi":"10.1093/ehjcvp/pvae042","title":"Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"Janssen Research and Development; HORIZON EUROPE Framework Programme; H. Lundbeck A/S; Servier; Teva Pharmaceutical Industries; Novo Nordisk; Idorsia Pharmaceuticals; Cytokinetics; Daiichi Sankyo Europe; European Commission; Deutsches Zentrum für Herz-Kreislaufforschung; Boston Scientific Corporation; Bristol-Myers Squibb; Universität Hamburg; AstraZeneca; Pfizer; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Internal medicine; Confidence interval; Thrombus; Odds ratio; Observational study; Meta-analysis; Randomized controlled trial; Stroke (engine); Cardiology; Clinical endpoint; Publication bias; Embolism","score_opus":0.07440930655182174,"score_gpt":0.3632297770646181,"score_spread":0.28882047051279636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399454668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068540605,0.995433,0.00007278373,0.00007321635,0.00013238282,0.0040467493,0.000046506462,0.000050666622,0.000076161734],"genre_scores_gemma":[0.0003171697,0.99828005,0.00011777394,0.00061897497,0.00018483917,0.000029941313,0.00008359851,0.0002401496,0.00012752347],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9921045,0.003739956,0.001655513,0.00076381525,0.0012933579,0.000442896],"domain_scores_gemma":[0.9979604,0.000060766764,0.0004692366,0.0009217511,0.00024381983,0.0003440451],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004529391,0.0008703428,0.014482155,0.0009880373,0.00010952791,0.00022762608,0.00018841926,0.00009273649,0.00023956678],"category_scores_gemma":[0.0000412728,0.0004882946,0.016241468,0.001557401,0.00006325857,0.00017161583,0.000062923216,0.0012020613,0.00011115681],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000099524605,0.000104283354,0.00009810555,0.38947818,0.60652304,0.0017542541,0.000033908254,0.000013984897,6.795727e-8,9.467455e-7,0.00049253507,0.0014907597],"study_design_scores_gemma":[0.00093097554,0.000101983984,0.00031462012,0.04135056,0.7913802,0.003199973,0.0000025013496,0.0000025451484,1.651451e-7,8.077693e-7,0.16231756,0.00039808083],"about_ca_topic_score_codex":0.0000064653773,"about_ca_topic_score_gemma":3.946184e-7,"teacher_disagreement_score":0.34812763,"about_ca_system_score_codex":0.00019194234,"about_ca_system_score_gemma":0.00012868055,"threshold_uncertainty_score":0.9997569},"labels":[],"label_agreement":null},{"id":"W4401686345","doi":"10.1093/ehjcvp/pvae058","title":"Management of dyslipidaemia in patients with comorbidities: facing the challenge","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Kidney disease; Ezetimibe; Intensive care medicine; Internal medicine; Dialysis; Diabetes mellitus; Dyslipidemia; PCSK9; Statin; Renal replacement therapy; Alirocumab; Clinical trial; Cholesterol; Disease; Endocrinology; Lipoprotein; LDL receptor","score_opus":0.05612760648022262,"score_gpt":0.340625694163217,"score_spread":0.28449808768299434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401686345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032442942,0.99281275,0.00008748406,0.00011348795,0.0007441641,0.0027162647,0.000027494701,0.00005315753,0.003120765],"genre_scores_gemma":[0.0009874521,0.99652123,0.00018231235,0.00017431636,0.0015313292,0.000054587967,0.000027532802,0.00034336135,0.00017787378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99335235,0.0021207756,0.0013173514,0.0006566312,0.0019311062,0.000621786],"domain_scores_gemma":[0.99770325,0.000043522166,0.0003196919,0.0014335219,0.00022274781,0.00027729006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0052201003,0.00075190683,0.0033194283,0.00046380254,0.0001742666,0.000102943624,0.0004491541,0.00011478999,0.000096898046],"category_scores_gemma":[0.00000840567,0.00040630647,0.005545863,0.0007466912,0.00011853386,0.0001097639,0.00012456132,0.002191271,0.00010882264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000809009,0.00017144658,0.000031292806,0.025828421,0.023902884,0.0018637992,0.00024957125,0.00002991229,1.7247447e-7,0.000014291808,0.0010726617,0.94675463],"study_design_scores_gemma":[0.003424954,0.00029654166,0.00040281695,0.035914935,0.009063077,0.0010463335,0.00006890875,0.0000016615538,0.00000161064,0.0000030883373,0.94938904,0.00038702926],"about_ca_topic_score_codex":0.000015639485,"about_ca_topic_score_gemma":3.850941e-7,"teacher_disagreement_score":0.9483164,"about_ca_system_score_codex":0.00036613416,"about_ca_system_score_gemma":0.00025554094,"threshold_uncertainty_score":0.9998389},"labels":[],"label_agreement":null},{"id":"W4402324926","doi":"10.1093/ehjcvp/pvae064","title":"Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"Daiichi Sankyo Company; H. Lundbeck A/S; Abbott Vascular; Aboca S.p.A. Società Agricola; Novo Nordisk; Daiichi Sankyo Europe; Bayer HealthCare; Boston Scientific Corporation; Idorsia Pharmaceuticals; AbbVie; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; ZonMw; Boehringer Ingelheim; Society for Music Theory; Bayer; Medtronic","keywords":"Antithrombotic; Pharmacotherapy; Medicine; Statement (logic); Group (periodic table); Thrombosis; Internal medicine; Cardiology; Intensive care medicine; Physical therapy; Political science; Physics","score_opus":0.1652904467160594,"score_gpt":0.3973753645242923,"score_spread":0.23208491780823287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402324926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012962658,0.9775495,0.00033998478,0.00063852256,0.0023275793,0.0034143345,0.00010046709,0.00009719218,0.0025697912],"genre_scores_gemma":[0.080761746,0.912642,0.00041382914,0.00203406,0.0035806913,0.000031740055,0.000027904196,0.00047208832,0.00003596103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9571146,0.03585923,0.0029851217,0.0016125614,0.001456936,0.0009716004],"domain_scores_gemma":[0.994752,0.0012973915,0.001445413,0.0018568708,0.00022988579,0.0004184224],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.026970742,0.001601147,0.007716084,0.00031182877,0.0006681481,0.000094399504,0.0009411627,0.0003280299,0.000024352174],"category_scores_gemma":[0.000044142354,0.0009161988,0.01829991,0.00069548603,0.0025038053,0.00006170377,0.0003397825,0.0039304397,0.00003274821],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020776268,0.0007179893,0.0020528988,0.004578274,0.29244766,0.0011253672,0.0009949158,0.001330366,0.0019983924,0.00007740008,0.020978227,0.67162085],"study_design_scores_gemma":[0.019415958,0.001577851,0.0044395835,0.008634377,0.023050724,0.0016554384,0.00012128816,0.000050270457,0.00018780239,0.000022651724,0.94005257,0.0007915087],"about_ca_topic_score_codex":0.000011564424,"about_ca_topic_score_gemma":1.600826e-7,"teacher_disagreement_score":0.9190743,"about_ca_system_score_codex":0.00026458665,"about_ca_system_score_gemma":0.00021946689,"threshold_uncertainty_score":0.9996736},"labels":[],"label_agreement":null},{"id":"W4402543585","doi":"10.1093/ehjcvp/pvae068","title":"Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Sanofi; LEO Pharma; Pfizer; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Medicine; Randomized controlled trial; Ambulatory; Cancer; Meta-analysis; Incidence (geometry); Internal medicine; Pancreatic cancer; Surgery; Stroke (engine)","score_opus":0.1533962540224156,"score_gpt":0.42888617191082506,"score_spread":0.2754899178884095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402543585","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006988876,0.982731,0.00040990938,0.0001512941,0.00030791393,0.0160269,0.0002725375,0.000011383862,0.00001918695],"genre_scores_gemma":[0.0002491508,0.99785435,0.000074812655,0.00042436444,0.00022189794,0.0008738844,0.00012765902,0.000110820714,0.000063053754],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98476136,0.009610763,0.00410476,0.0004377712,0.00084686157,0.00023851504],"domain_scores_gemma":[0.9958992,0.0009958463,0.002188507,0.00050804537,0.0003114233,0.000096956006],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.025087783,0.0005365744,0.030813958,0.0006334681,0.000068810616,0.000073314586,0.00020256334,0.000075232165,0.00015389384],"category_scores_gemma":[0.00040794053,0.0002707539,0.025712484,0.00075219607,0.00008077882,0.00009471205,0.000052486615,0.00034670124,0.0000029405812],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002631206,0.00025235058,3.0170827e-7,0.40629202,0.5849944,0.0000046175496,0.0001048673,0.000018266728,0.000022249546,0.0000029738,0.003024229,0.0050206315],"study_design_scores_gemma":[0.014288028,0.000081321596,0.000021337573,0.04412867,0.9005016,0.000020511401,0.0000037440075,0.000019798244,0.000005950903,0.0000043206037,0.04073277,0.00019194618],"about_ca_topic_score_codex":0.000026215414,"about_ca_topic_score_gemma":8.144715e-7,"teacher_disagreement_score":0.36216336,"about_ca_system_score_codex":0.00010081,"about_ca_system_score_gemma":0.00012193749,"threshold_uncertainty_score":0.9999745},"labels":[],"label_agreement":null},{"id":"W4403502574","doi":"10.1093/ehjcvp/pvae080","title":"Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"Icahn School of Medicine at Mount Sinai; AstraZeneca","keywords":"Ticagrelor; Medicine; Aspirin; Percutaneous coronary intervention; Cardiology; Twilight; Conventional PCI; Internal medicine; Clopidogrel; Myocardial infarction","score_opus":0.027032535262793134,"score_gpt":0.3263635839791255,"score_spread":0.29933104871633237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403502574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95177627,0.046514943,0.000057912985,0.000041262312,0.00036809067,0.0011579868,0.000012485353,0.000026660447,0.000044362798],"genre_scores_gemma":[0.9947522,0.0044996613,0.000022484468,0.000050741048,0.0005187857,0.000010682577,0.0000013428167,0.00008169161,0.000062380794],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971629,0.0009813146,0.00047831974,0.00036805178,0.00077512587,0.0002343136],"domain_scores_gemma":[0.99918115,0.00005469875,0.00009533686,0.00035703098,0.00010399486,0.00020777338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011696998,0.0003070005,0.00076776586,0.00016285782,0.000111256406,0.000050985942,0.00009979961,0.00003598121,0.00011617513],"category_scores_gemma":[0.00001398751,0.0001614751,0.0018252273,0.00022799511,0.00012855906,0.00012494584,0.000051367133,0.00048558516,0.000003708019],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.428096,0.004084148,0.087214865,0.0011477813,0.097207084,0.01297177,0.007470526,0.000632081,0.021511097,0.0000019486301,0.0004131253,0.33924958],"study_design_scores_gemma":[0.22260417,0.067510046,0.4381381,0.008686836,0.017254671,0.22878645,0.0015272858,0.000727205,0.003839352,0.000010868877,0.009618449,0.0012965513],"about_ca_topic_score_codex":0.00000716452,"about_ca_topic_score_gemma":6.72336e-7,"teacher_disagreement_score":0.35092324,"about_ca_system_score_codex":0.00006130643,"about_ca_system_score_gemma":0.00009593934,"threshold_uncertainty_score":0.65847635},"labels":[],"label_agreement":null},{"id":"W4403526074","doi":"10.1093/ehjcvp/pvae071","title":"Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Type 2 diabetes; Medicine; Arterial disease; Internal medicine; Baseline (sea); Peripheral; STRIDE; Diabetes mellitus; Disease; Cardiology; Physical therapy; Physical medicine and rehabilitation; Vascular disease; Endocrinology; Political science","score_opus":0.03299657911773132,"score_gpt":0.3013223683047773,"score_spread":0.26832578918704597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403526074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97848547,0.018058429,0.001183828,0.00080299866,0.00028285175,0.0011128256,0.000006120142,0.00003847563,0.000029001283],"genre_scores_gemma":[0.9956904,0.0018154435,0.00095795427,0.0008727143,0.0004687395,0.000016743776,0.0000033774133,0.00007979038,0.000094833544],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99669236,0.0016935773,0.00046560145,0.00030217093,0.0005735955,0.0002726808],"domain_scores_gemma":[0.9991222,0.00012452512,0.00007769918,0.0003155474,0.000096360796,0.00026366618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030205303,0.00023795899,0.00052159093,0.00013415514,0.000105364656,0.00015342698,0.00009397454,0.000015244551,0.00008288883],"category_scores_gemma":[0.00008252975,0.00015220056,0.00029932646,0.00031351377,0.000087690976,0.00013442538,0.000048551025,0.0003143762,0.00000401591],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06103114,0.0015019341,0.3007346,0.0065535614,0.02493637,0.0055220765,0.0069168997,0.014981083,0.1201571,0.000015304227,0.005711367,0.45193854],"study_design_scores_gemma":[0.048714098,0.002353612,0.78413284,0.0041341176,0.004520647,0.0010560516,0.00014730275,0.1410582,0.0006947937,0.00003861095,0.0124366535,0.0007130846],"about_ca_topic_score_codex":0.000002266066,"about_ca_topic_score_gemma":2.694626e-7,"teacher_disagreement_score":0.4833982,"about_ca_system_score_codex":0.00007194404,"about_ca_system_score_gemma":0.00015806539,"threshold_uncertainty_score":0.6206559},"labels":[],"label_agreement":null},{"id":"W4405781056","doi":"10.1093/ehjcvp/pvae097","title":"Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; BC Innovation Council; Population Health Research Institute; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Dalhousie University; Health Sciences North; University of Toronto; University of British Columbia; NOSM University; Queen's University","funders":"University of Toronto","keywords":"Amiodarone; Meta-analysis; Medicine; Internal medicine; Atrial fibrillation","score_opus":0.26831761765370454,"score_gpt":0.419657090819918,"score_spread":0.15133947316621343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405781056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000138592195,0.99666697,0.0003979063,0.00028002524,0.00006427266,0.0024842825,0.000045901674,0.000017429147,0.000029382576],"genre_scores_gemma":[0.00011274681,0.9988214,0.00017508629,0.00019701904,0.00025211586,0.000008812827,0.000006860992,0.00008572636,0.00034024773],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9940629,0.0032739476,0.0013731094,0.00034660214,0.0007657917,0.00017762727],"domain_scores_gemma":[0.99771184,0.0003637263,0.0010272892,0.0005514801,0.00019992585,0.00014577087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005686004,0.00047950997,0.008938676,0.00043720307,0.00009875222,0.000111446556,0.00013378517,0.000037720318,0.00007412992],"category_scores_gemma":[0.00008303477,0.00020707346,0.009536362,0.0008609395,0.00013130905,0.00010940493,0.00007221656,0.0005557148,0.0000066240646],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007785135,0.000003983789,0.000016150103,0.35738248,0.6359277,0.000044080934,0.000060008944,0.000014366957,9.033581e-7,0.000004322017,0.00046197535,0.0060762963],"study_design_scores_gemma":[0.0002823899,0.00005194015,0.000008736959,0.016769506,0.6247741,0.0004572896,0.000009768872,0.0000057932407,6.5674965e-7,2.4497373e-7,0.35751978,0.00011978277],"about_ca_topic_score_codex":0.0000055227706,"about_ca_topic_score_gemma":2.020287e-7,"teacher_disagreement_score":0.3570578,"about_ca_system_score_codex":0.000027517277,"about_ca_system_score_gemma":0.0000471816,"threshold_uncertainty_score":0.9617677},"labels":[],"label_agreement":null},{"id":"W4405796144","doi":"10.1093/ehjcvp/pvae095","title":"Management of dyslipidaemia in patients with comorbidities—facing the challenge","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Discontinuation; Medicine; Disease; Intensive care medicine; Liver disease; Pharmacology; Internal medicine","score_opus":0.0581799620643923,"score_gpt":0.34206540601398544,"score_spread":0.28388544394959314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405796144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006703549,0.9947779,0.000005941866,0.0001106576,0.00047037168,0.0017326723,0.000041769446,0.000029744397,0.0021605825],"genre_scores_gemma":[0.0021562732,0.9966584,0.000062418294,0.00013453646,0.0005920587,0.00005377237,0.00003828617,0.00020330735,0.000100945654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628234,0.0011019548,0.0007945177,0.00045614026,0.0009961837,0.00036883866],"domain_scores_gemma":[0.9986881,0.00005163989,0.0002126454,0.00070682185,0.00013249015,0.0002083227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013168319,0.0005545945,0.0019513201,0.00029966884,0.00010454749,0.00007750936,0.00026168875,0.000051208426,0.00013610013],"category_scores_gemma":[0.0000030055,0.00028588524,0.0030048634,0.0003854148,0.00007211322,0.000076732955,0.00008055482,0.0009108849,0.00012244642],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010812929,0.00071806094,0.0005789541,0.015665818,0.04073968,0.0043663154,0.00026118703,0.000022854196,7.673051e-8,0.000015567182,0.0028639317,0.9346594],"study_design_scores_gemma":[0.003727215,0.00027314643,0.0028507714,0.03355191,0.015991688,0.0002511273,0.00003471841,9.3825923e-7,0.0000014967108,0.000001948234,0.9430413,0.0002736971],"about_ca_topic_score_codex":0.000005287186,"about_ca_topic_score_gemma":1.4518797e-7,"teacher_disagreement_score":0.9401774,"about_ca_system_score_codex":0.00028213856,"about_ca_system_score_gemma":0.00011731353,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W4406288034","doi":"10.1093/ehjcvp/pvae090","title":"Prevention is the key","year":2024,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Key (lock); Computer science; Computer security","score_opus":0.3696574014884091,"score_gpt":0.45268941951954444,"score_spread":0.08303201803113536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406288034","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09675132,0.6360142,0.058881953,0.1590828,0.01019081,0.0018313421,0.00016667211,0.00044318597,0.036637686],"genre_scores_gemma":[0.7682587,0.046311244,0.0048023374,0.14032602,0.023932965,0.00010571379,0.00002541327,0.00067828374,0.015559315],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394166,0.002390605,0.0024260252,0.000524365,0.00027162448,0.0004457265],"domain_scores_gemma":[0.9982964,0.00033410988,0.00042660782,0.00064433273,0.00006792939,0.0002306638],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.04333687,0.00024704324,0.00073696976,0.00028678114,0.00050434005,0.0006595357,0.00043731695,0.00005127095,0.002213717],"category_scores_gemma":[0.00022795392,0.00022255517,0.0018131139,0.00031005952,0.0000695026,0.0006510192,0.00003965238,0.00064116955,0.0103375185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002838015,0.00010246805,0.0015663804,0.00030536784,0.006078078,0.000108678556,0.0090486705,0.0013042068,0.00022370864,0.00715558,0.9563477,0.017730761],"study_design_scores_gemma":[0.0006538059,0.000050950413,0.0020771225,0.00012483001,0.00005175033,0.0004920038,0.00014795775,0.0014131189,0.00006103707,0.0024929908,0.99217445,0.00025999983],"about_ca_topic_score_codex":0.00003506545,"about_ca_topic_score_gemma":6.2739645e-7,"teacher_disagreement_score":0.6715074,"about_ca_system_score_codex":0.00028725973,"about_ca_system_score_gemma":0.000117334035,"threshold_uncertainty_score":0.9986984},"labels":[],"label_agreement":null},{"id":"W4408266667","doi":"10.1093/ehjcvp/pvaf012","title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024","year":2025,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Pharmacotherapy; Medicine; Intensive care medicine; Clinical trial; Drug; Adverse effect; Pharmacology; Drug class; Internal medicine","score_opus":0.0968439457589175,"score_gpt":0.3931756809318988,"score_spread":0.2963317351729813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408266667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040421775,0.9852649,0.0035134584,0.00049860956,0.0019089306,0.0036373946,0.000029106026,0.00018047809,0.004926683],"genre_scores_gemma":[0.00003774869,0.98701125,0.002994181,0.0014925814,0.0031720516,0.00009637883,0.000041788535,0.0003055214,0.0048485193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99155706,0.002608112,0.0016765887,0.001458885,0.001499536,0.001199787],"domain_scores_gemma":[0.9973956,0.0001894728,0.0002628817,0.0009611005,0.00014561428,0.0010453779],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003960859,0.0015397869,0.005505196,0.0013677392,0.00030293883,0.0004799801,0.0005424291,0.00029970074,0.0014474478],"category_scores_gemma":[0.000030766812,0.0012019082,0.008688003,0.0011939709,0.00013068301,0.00040489103,0.00020957392,0.0024794468,0.00021634405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015094543,0.00038757786,0.00002910431,0.0047005233,0.041920926,0.0048368666,0.00012667676,0.00014434019,0.00007663759,0.000016503405,0.0722508,0.8753591],"study_design_scores_gemma":[0.0117906565,0.0002423483,0.00008075056,0.0070527866,0.016843446,0.0036763083,0.000046577094,0.000016415808,0.000021053835,0.000009357791,0.9593166,0.0009036738],"about_ca_topic_score_codex":0.000054165845,"about_ca_topic_score_gemma":0.0000010317577,"teacher_disagreement_score":0.8870658,"about_ca_system_score_codex":0.00050929846,"about_ca_system_score_gemma":0.0011878753,"threshold_uncertainty_score":0.9998219},"labels":[],"label_agreement":null},{"id":"W4410559593","doi":"10.1093/ehjcvp/pvaf023","title":"Management of dyslipidaemia in patients with comorbidities—facing the challenge: type 1 diabetes mellitus","year":2025,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Lipid profile; Randomized controlled trial; Type 2 Diabetes Mellitus; Clinical trial; Endocrinology","score_opus":0.036105513960645784,"score_gpt":0.3124212168235835,"score_spread":0.2763157028629377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410559593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005963012,0.98968863,0.000013781273,0.00009077664,0.0006539571,0.0021349299,0.000011551978,0.000035500943,0.0067745666],"genre_scores_gemma":[0.00065752084,0.9977971,0.00018635085,0.00021056131,0.00033327978,0.00003713274,0.00005551834,0.0001346668,0.0005878982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99599886,0.0012575622,0.0008696073,0.00046177884,0.00089356804,0.0005186075],"domain_scores_gemma":[0.99836636,0.000103696824,0.0003062888,0.0008750583,0.00020649952,0.00014209628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019170674,0.000598632,0.0023335468,0.00045609756,0.00013353038,0.00006907125,0.00038784882,0.00006320703,0.00012260782],"category_scores_gemma":[0.000010125049,0.00035226223,0.0018474789,0.0006869327,0.00008570858,0.00009589031,0.00012730218,0.0007790877,0.000043310294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007404854,0.00034655636,0.00047926538,0.013715441,0.022400394,0.0003117993,0.000077831544,0.000038398986,1.8770002e-7,0.000014614012,0.0019197945,0.96062165],"study_design_scores_gemma":[0.0040883166,0.00037161566,0.0013074838,0.027141724,0.007919668,0.000012343421,0.000024606317,0.0000013165076,0.000004921058,0.0000026831754,0.95882404,0.00030129787],"about_ca_topic_score_codex":0.0000020128077,"about_ca_topic_score_gemma":1.4824718e-7,"teacher_disagreement_score":0.96032035,"about_ca_system_score_codex":0.00023656272,"about_ca_system_score_gemma":0.000104360915,"threshold_uncertainty_score":0.99989295},"labels":[],"label_agreement":null},{"id":"W4413394227","doi":"10.1093/ehjcvp/pvaf064","title":"Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Health Care Foundation","funders":"American Regent; National Institutes of Health; Novo Nordisk; University of Glasgow; ARCA Biopharma; LivaNova; Boston Scientific Corporation; Alexion Pharmaceuticals; Novartis Portugal; Alnylam Pharmaceuticals; Idorsia Pharmaceuticals; British Heart Foundation; Brigham and Women's Hospital; Intas Pharmaceuticals; Eli Lilly and Company; AstraZeneca; Bayer; Amgen; American Heart Association","keywords":"Medicine; Valsartan; Sacubitril, Valsartan; Sacubitril; Internal medicine; Clinical endpoint; Enalapril; Ejection fraction; Logistic regression; Cardiology; Quality of life (healthcare); Heart failure; Clinical trial; Angiotensin-converting enzyme; Blood pressure","score_opus":0.13902949729123087,"score_gpt":0.33451188158451123,"score_spread":0.19548238429328035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413394227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837297,0.010241221,0.0034266124,0.0011901883,0.0001928144,0.0010577785,0.000013991177,0.000031651045,0.000116006675],"genre_scores_gemma":[0.99526584,0.0012600517,0.0018950707,0.0012107046,0.00017009121,0.0000056114486,0.000007520295,0.00006230156,0.00012280639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963469,0.0014703629,0.00066912896,0.00042187737,0.00073830824,0.00035342394],"domain_scores_gemma":[0.99873173,0.00009212381,0.00018028638,0.00046337312,0.00030156228,0.00023089538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002792945,0.00034441563,0.00097208784,0.0002939686,0.00029473077,0.00008593557,0.00011775433,0.00005038193,0.000019584431],"category_scores_gemma":[0.00008665326,0.00022568337,0.00036131527,0.00041248713,0.00016899766,0.00022435226,0.00008396448,0.00048345,0.0000027118283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015496721,0.00056398,0.96624994,0.00034274772,0.0036923136,0.00016884018,0.00051718845,0.0004735255,0.008361511,0.000046236368,0.0012966164,0.016737424],"study_design_scores_gemma":[0.014101529,0.00028211527,0.97575223,0.0008519653,0.000659885,0.00007424861,0.000081792794,0.0002158362,0.0007181513,0.000012317323,0.007013205,0.00023672887],"about_ca_topic_score_codex":0.00020437218,"about_ca_topic_score_gemma":0.000026182874,"teacher_disagreement_score":0.016500695,"about_ca_system_score_codex":0.0001021126,"about_ca_system_score_gemma":0.00016602044,"threshold_uncertainty_score":0.92031},"labels":[],"label_agreement":null},{"id":"W4413844000","doi":"10.1093/ehjcvp/pvaf063","title":"Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Université de Bordeaux; Société Française de Médecine Vasculaire","keywords":"Rivaroxaban; Atrial fibrillation; Apixaban; Medicine; Cardiology; Internal medicine; Peripheral; Arterial disease; Vascular disease; Warfarin","score_opus":0.017478355320167113,"score_gpt":0.29471366248526026,"score_spread":0.27723530716509315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413844000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907971,0.0066952435,0.0009962742,0.00032806062,0.0002217306,0.00076118467,0.000004572356,0.000019382198,0.00017647221],"genre_scores_gemma":[0.9972499,0.001828444,0.00018363977,0.000108723296,0.0005468629,2.5208908e-7,0.00000731539,0.000029284016,0.0000455496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981484,0.0007776459,0.0003431066,0.00023408528,0.00033494428,0.00016184254],"domain_scores_gemma":[0.9994267,0.00008419669,0.00007774406,0.00017483208,0.0000934133,0.00014308882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001094738,0.00017338937,0.0005095482,0.0002247456,0.00010559956,0.00004539229,0.000038225673,0.00002175135,0.000025996003],"category_scores_gemma":[0.00003614545,0.0001366938,0.00044972048,0.0002024414,0.00007078635,0.00017634498,0.000030278225,0.00015412438,0.000001061973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008400056,0.000008159092,0.9581586,0.00016440138,0.0014561212,0.00003560935,0.00009061943,0.0016323552,0.00025176784,0.00001559387,0.000033491302,0.029753197],"study_design_scores_gemma":[0.017532894,0.00019356895,0.9589398,0.00028230512,0.00043204502,0.000018323835,0.000009624347,0.00014132127,0.00007240404,0.000013624501,0.022238808,0.00012528773],"about_ca_topic_score_codex":0.000003743784,"about_ca_topic_score_gemma":1.3084617e-7,"teacher_disagreement_score":0.02962791,"about_ca_system_score_codex":0.000052458323,"about_ca_system_score_gemma":0.000041417057,"threshold_uncertainty_score":0.55742115},"labels":[],"label_agreement":null},{"id":"W4414314196","doi":"10.1093/ehjcvp/pvaf069","title":"An old drug in a new era: digitoxin in the spotlight after DIGIT-HF","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Chemical Reactions and Isotopes","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Drug; Digitoxin; Diabetes mellitus; MEDLINE; Feature (linguistics)","score_opus":0.058978978501512964,"score_gpt":0.40982498973133585,"score_spread":0.3508460112298229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414314196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96202624,0.018244017,0.00015080353,0.0039850255,0.0013498088,0.0006219362,0.000012159941,0.000073450836,0.013536587],"genre_scores_gemma":[0.9746668,0.0066874307,0.00010860801,0.015255435,0.0014602818,0.000028461312,0.0000059324775,0.000065173364,0.001721875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946866,0.0030483545,0.00070935994,0.0004771605,0.0004056588,0.0006728509],"domain_scores_gemma":[0.9986741,0.00030917427,0.00008096351,0.00053505914,0.00006677998,0.00033395694],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0034966748,0.00037677493,0.00054814183,0.00040045526,0.00023016451,0.00026018813,0.0007129894,0.000116918716,0.0006846269],"category_scores_gemma":[0.00005312788,0.00028368985,0.0009059847,0.0008497317,0.000118737815,0.00049051497,0.000055869805,0.0026091773,0.00014931938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041191895,0.003541528,0.097658224,0.000109003464,0.0038897817,0.0062875147,0.008628966,0.006515182,0.14697649,0.00033376593,0.15502824,0.5669121],"study_design_scores_gemma":[0.004534126,0.000057984886,0.026555171,0.00007465597,0.00014444122,0.00036162688,0.00014272558,0.00013455427,0.017989071,0.00020655646,0.9494851,0.0003139504],"about_ca_topic_score_codex":0.000070638715,"about_ca_topic_score_gemma":0.000028566625,"teacher_disagreement_score":0.7944569,"about_ca_system_score_codex":0.00016642555,"about_ca_system_score_gemma":0.00020622877,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W4415609456","doi":"10.1093/ehjcvp/pvaf076","title":"Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Type 2 Diabetes Mellitus; Diabetes mellitus; Type 2 diabetes; Statin; Clinical trial; Lipid profile","score_opus":0.016902788158410554,"score_gpt":0.26967036763984314,"score_spread":0.2527675794814326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415609456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8909445,0.09717799,0.00035246753,0.00059589307,0.00082457036,0.0012794135,0.000006709417,0.000057839978,0.008760614],"genre_scores_gemma":[0.9828123,0.01531258,0.00041428252,0.00074117386,0.00039589332,0.000015295289,0.000009204445,0.00008919678,0.00021010844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99653465,0.0009937998,0.0005953818,0.00038097947,0.0009898074,0.00050538656],"domain_scores_gemma":[0.9984512,0.000056560282,0.0001243751,0.0008644536,0.00035850942,0.00014492014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028664991,0.00033218332,0.0009538848,0.0003020244,0.00019271312,0.00006695918,0.00031041927,0.00004645474,0.000096897755],"category_scores_gemma":[0.00002286364,0.00022213657,0.0011825175,0.0006452081,0.00014781328,0.00014292532,0.00007295722,0.00070007547,0.000024783521],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009739157,0.0007531999,0.043033566,0.0010630154,0.033236206,0.0005092404,0.0010974327,0.002807316,0.00021288864,0.00005566125,0.0032175167,0.91304004],"study_design_scores_gemma":[0.015949808,0.0006029213,0.52581537,0.0021254804,0.0019347373,0.000037017748,0.0003835999,0.00004881294,0.0031856864,0.000037077843,0.44944295,0.00043653697],"about_ca_topic_score_codex":0.000053158452,"about_ca_topic_score_gemma":0.0000020426435,"teacher_disagreement_score":0.9126035,"about_ca_system_score_codex":0.00012453504,"about_ca_system_score_gemma":0.0000726018,"threshold_uncertainty_score":0.90584666},"labels":[],"label_agreement":null},{"id":"W7117728034","doi":"10.1093/ehjcvp/pvaf091","title":"The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Etiology; Thrombus; Left ventricular thrombus; Anticoagulant therapy; Anticoagulant; Thrombosis; Oral anticoagulant","score_opus":0.053361306322746584,"score_gpt":0.3740801899925749,"score_spread":0.3207188836698283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117728034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92144173,0.069408365,0.0065440973,0.0004659325,0.00055170833,0.0013316316,0.0000016261145,0.0000116836445,0.00024319788],"genre_scores_gemma":[0.9894182,0.00994374,0.00014412143,0.0000443343,0.00037767066,0.0000027284248,0.0000017499481,0.000017855544,0.000049606813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983637,0.0007897301,0.00038614968,0.00012110769,0.00018692213,0.00015240994],"domain_scores_gemma":[0.99882996,0.00069096906,0.000116006566,0.00022929654,0.000108323795,0.00002541455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019012775,0.00011295812,0.00043750828,0.00012905653,0.00016841208,0.000017615614,0.000086536944,0.000021212305,0.00000866085],"category_scores_gemma":[0.000052414933,0.0000625068,0.0010148884,0.00017313458,0.000063093496,0.00003954494,0.000010845334,0.000072538154,0.0000012228244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014721423,0.0000752282,0.47172302,0.00009578886,0.0068271416,0.000038149275,0.0004967456,0.01413201,0.05490197,0.00017366251,0.000049217586,0.45001492],"study_design_scores_gemma":[0.00659553,0.00038309576,0.62603074,0.00010407756,0.00081387063,0.00007318664,0.00012689686,0.0016645751,0.04658014,0.00011830095,0.31743765,0.00007193773],"about_ca_topic_score_codex":0.0000061963606,"about_ca_topic_score_gemma":4.343936e-7,"teacher_disagreement_score":0.449943,"about_ca_system_score_codex":0.000057808567,"about_ca_system_score_gemma":0.00003666957,"threshold_uncertainty_score":0.25489533},"labels":[],"label_agreement":null}]}